CA1189431A - Multi-zoned reaction vessel having pressure- actuatable control means between zones - Google Patents

Multi-zoned reaction vessel having pressure- actuatable control means between zones

Info

Publication number
CA1189431A
CA1189431A CA000382977A CA382977A CA1189431A CA 1189431 A CA1189431 A CA 1189431A CA 000382977 A CA000382977 A CA 000382977A CA 382977 A CA382977 A CA 382977A CA 1189431 A CA1189431 A CA 1189431A
Authority
CA
Canada
Prior art keywords
zone
liquid
vessel
passageway
zones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000382977A
Other languages
French (fr)
Inventor
Richard L. Columbus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eastman Kodak Co
Original Assignee
Eastman Kodak Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22859590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA1189431(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eastman Kodak Co filed Critical Eastman Kodak Co
Application granted granted Critical
Publication of CA1189431A publication Critical patent/CA1189431A/en
Expired legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502738Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by integrated valves
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5302Apparatus specially adapted for immunological test procedures
    • G01N33/5304Reaction vessels, e.g. agglutination plates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00Additional constructional details
    • B01L2300/08Geometry, shape and general structure
    • B01L2300/0809Geometry, shape and general structure rectangular shaped
    • B01L2300/0825Test strips
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00Moving or stopping fluids
    • B01L2400/04Moving fluids with specific forces or mechanical means
    • B01L2400/0403Moving fluids with specific forces or mechanical means specific forces
    • B01L2400/0406Moving fluids with specific forces or mechanical means specific forces capillary forces
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00Moving or stopping fluids
    • B01L2400/04Moving fluids with specific forces or mechanical means
    • B01L2400/0475Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
    • B01L2400/0487Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure fluid pressure, pneumatics
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00Moving or stopping fluids
    • B01L2400/06Valves, specific forms thereof
    • B01L2400/0688Valves, specific forms thereof surface tension valves, capillary stop, capillary break
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/807Apparatus included in process claim, e.g. physical support structures
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555Hetero-N
    • Y10T436/147777Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/17Nitrogen containing
    • Y10T436/173845Amine and quaternary ammonium
    • Y10T436/175383Ammonia
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]

Abstract

Abstract A reaction vessel, test device, and method of detection or measurement are disclosed, featuring the use of at least two operatively connected zones formed by transport surfaces spaced apart throughout most of the zones a capillary distance. The zones are fluidly con-nected by meniscus control means effective to stop cap-illary flow of the liquid from one zone to the other, until an externally generated actuation pressure is applied.

Description

q~

MULTI-ZONED REACTION VESSEL HAVING PRESSURE-ACTUATABLE
CONTROL MEANS BETW~EN ZONES
Field of the Invention The invention rela~es to a reac~ion vessel, a test device, and methods of detection or measure~ent use-ful ;n the interaction of liquids and reagents. A pre-ferred use is the measurement of the amount of analytes in liquids.
Back~round of the Invention In ~y previous application S.N. 954,689, now U.S.
Pater~t No. 4,233,029, I describe a liquid transport device formed by opposed surfaces spaced apart a distance effec-tive to provide, through a zone of intended transport, capillary flow of liquid. Once the liquid is introduced into such a device, it continues to flow between the sur-faces until either the volume of liquid is exhausted or an edge of the zones is encountered. There is no capability for temporarily stopping liquid flow within a portion of the device, and thereafter resuming the flow, other than by adding more liquid to an exhausted supply of liquid.
Temporary stoppage and resumption of flow would be particularly useful for sequential reactions conducted on a constant volume of liquid, such as in an assay of the liquid using sequential reagen~s separated within the device. The addition of more liquid to cause resumption of flow is not a useful technique when the reaction dictates that the liqu;d volume or concentration of analyte must remain constant.
Accordingly, what has been desired is a reaction 3 vessel or test device featuring capillary attraction as the means for moving liquid therein, the device being operative to temporarily stop the flow of a given ~olume of liquid to allow a reaction with a reagent, and there-after to resume the flow of the liquid for further pro-cessing. Such a device would permit immunoassays to be condu~ted, for example, using labeled antigens or anti-bodies, and the complementary immunogen as the reagent that reacts (by binding) while the liquid is temporarily LJ~

stopped. Resumed flow would cause separation of the bound and of the Iree labeled antigen or antibody into two different zones of the device, permit~ing accurate de~ection of the labeled an~igen or antibody, and the calculation of the liquid immunogen that is present-Related ~E~ications My U.S. Patent 4,310~399 issued January 12, 1982, entitled i~L.iquid Transport Device ContMining Means for Delayi.ng Capillary Flow,~ describes a capillary transport 10 device having ~eans for delaying liquid ~low between two regions. The specifically detailed embodiment described therein is one in which the liquid flow ra~e is retard~d, but no~ significantly stopped, by the delaying means.
S~MMARY OF IH~ lNV~NTlON
This invention is directed to a multi-zoned reacLion vessel and a method for controlling flow from one zone to the other, that pe~mits the use of capillary attraction as the force that moves the liquid. That is 9 capillary flow is temporarily stopped by the configuration 20 of the vessel between the zones, in a manner which permits subsequent resumption or reactivation of liquid flow.
More specifically, in one aspect of the inven-tlon, there is provided an improved reaction vessel com-prising first and second fluidly connected zones9 inlet 25 means permitting the introduction of liquLd Tnto the first zone, and a passageway connecting the zone6. The first zone contains a reagent capable of in~eracting wlth a material of the liquid 9 and the second zone is adapted to receive the liquid from the first zone. The first and 30 second ~ones comprise a first member, a cover member, and means for disposing the flrst member and the cover member ln superposed relationship, the first nd the cover members having opposed surfaces providing transport of liquid lntroduced between them~ The lmprovement of the 35 vessel results, in part 9 from the fact ~hat the opposed surfaces are spaced apart a distance that is effective to induce capillary flow of ~he ln~roduced li~uid at least in 8~LD~l3:~

the portion of the first zone contiguous to the passage-way, and in the second zone. The improvement also results from the fact that the passageway includes meniscus con-trol means for temporarily stopping the liquid meniscus from proceedin~ into the second zone from the first zone.
The control means is confi~ured to permit the liquid to flow into the second zone only upon the application to the liquid of an externally generated pressure sufficient to push the meniscus into the second zone.
In an alternate aspect of the invention, the spaced-apart distance of the second zone is less than that of the first zone, by a selected amount. The selected amount is effective to preferentially attract the liquid, in response to the push of the liquid by the pressure, into the second zone from the first zone and to confine the attracted liquid within the second zone.
In a further alternate aspect of the invention, at least one of the opposed surfaces comprises, in both of the zones, a relatively non-wettable material coated with 2G a surfactant soluble in the liquid and capable of making the surfaces wettable by the liquid. The effect is that the non-wettable surface material returns to its relatively non~wettable condition after the liquid leaves a given zone, insuring that flow will proceed preferentially to the downstream zone.
In yet another aspect of the invention, the reaction vessel described above is a test device and the reagent of the first zone is a) immobilized in the first zone, and b~ capable of interacting with an analyte of choice. Immunoassays are possible using such a device, wherein a labeled amount, that is, the analyte analog, is included in the first zone, preferably to compete with the unlabeled analyte of the liquid for a bonding reaction with the reagent. As used herein, "analog" refers to a labeled antigen corresponding to an antigen to be assayed, or a labeled antibody corresponding to a particular antibody to be assayed. Selection of either an antibody or an antigen as the reagent of the first zone serves to immobilize a portion of both the analog and either the patient antigen or antibody, respectively.
In yet another aspect of the invention, the reaction vessel described above permits the analysis of whole blood. The reagent of the first zone is a red cell-agglutinating reagent immovably adhered to the first zone, and the second zone contains a test element includ-ing at least one detection reagent specific to the analy-sis of the analyte of choice. The analyte is detectable from the plasma that is obtained from the first zone following the separation of the red cells in the first zone.
In still another aspect of the invention, a method is provided for interacting a material that is con-tained in a liquid, with a reagent. ~he method uses a device comprising two adjacent, fluidly connected zones both of which comprise opposed liquid transport surfaces, 20 spaced apart as described above. The first of the two zones includes the reagent. The method comprises the steps of a) filling the first zone with liquid, and b) retaining the liquid wi~hin the first zone while the reagent interacts with the material. Thereafter, the 25 method includes the steps of c) applying to the liquid in the first zone an externally generated pressure. The pressure is selected to be sufficient to push the meniscus of the l;quid from the first zone into the second zone.
Yet another aspect o the invention features a 30 method for detecting the amount of material that is either bound or unbound to a reagent chosen for its capability to bind the material, using a reaction vessel having first and second fluidly connected zones wherein the material and reagent interact in the first zone. The method com-35 prises placing a liquid containing an unknown amount othe material, in unlabeled form, in the first zone, along with a liquid containing a known amount of the material (the analo~) that is labeled for detection, the first zone further including the reagent immob;lized thereinO The liquid is retained in the first zone while the reagent binds with both the labeled and the unlabeled material.
The methocl is completed by applying to the liquid in the first zone an externally genera~ed pressure in an amount sufficient to force the material that is free of the reagent to start flowing into the second zone, and detecting the free labeled material in said second zone or the bound labeled material in the first zone.
It is a further aspect of the invention that a method is provided for determ;ning the amount of an analyte of whole blood in a test device comprisin~ two opposed transport surfaces and means for spacing them apart to provide at least two fluidly connected zones, The method comprises the steps of a) placing a quantity of whole blood within the first of the zones which contains a cell-agglutinating reagent that is incapable of moving out of the first zone, and b) retaining the quantity of whole blood in the first zone a length of time sufficient to cause blood cells to bind to the reagent and thus to separate from the blood plssma. Thereafter, the method comprises the steps of c) applying to the zone containing the plasma an externally generated pressure in an amount sufficient to force the plasma, but not the cells, to flow into the second of the zones, and detecting within the second zone a radiometric change resulting from the interaction between a detection reagent contained in the second zone and the analyte.
3 Thus, it is an advantage of the invention that temporary stoppage is achieved of capillary liquid flow from one zone to a second fluidly connected zone in a multi-zone reaction vessel.
Yet another advantage of the invention is that such stoppage of flow can be overcome by an externally generated pressure which is compatible with the desired processing. For example, the pressure can be applied without altering the liquid volume or concentration and without lycing the red cells of whole blood used as the liquid.
Still other and related advantages feature the use of such a device to analyze whole blood or conduct immunoassays.
Other features and advantages will become appar-ent upon reference to the fallowing Description of the 10 Preferred Embodiments when read in light of the attached drawin~s.
BRIEF DESCRIPTION OF THE DRAWINGS
Fi~. 1 is a plan view of a reaction vessel con~
structed in accordance with the invention, showing in 15 phantom certain alternate design configurations;
Fig. 2 is a section v;ew taken generally along the line II-II of Fig. 1 and illustrating the first steps in the use of the vessel;
Fig. 3 is a section view similar to that of Fig.
20 2 but schematically illustrating subsequent steps in its - use;
Fig. 4 is a fragmentary plan view of a device similar to that of Fig. 1, but which is a comparative e~ample rather than an embodiment of the invention;
Figs. 5 through 7 are fragmentary section views similar to that of Fig. 3, but illustrating alternate embodiments of the invention;
Figs. 8 and 9 are section views similar to ~hat of Fig. 3, but illustrating still other additional embodi-30 mentS;
Fig. lO is a plan view similar to that of Fig. 1,illustrating an embodiment partlcularly adapted for the detection or measurement of antibodies or antigerls;
Fig. 11 is a section view taken generally along 35 the line XI-XI of Fig. 10;
Figs. 12a and 12b are plan views demonstrating the use of the device of Fig. 10;
Fig. 13 is a section view similar to that of Figo ? or 3, illustrating an embodiment particularly adapted for detection of an analyte of whole blood;
Fig. 1~ is a plan view sim;lar to that of Fig.
12a, b~t illustrating a three-zone embodiment; and Fig. ~5 is a section view taken generally along the line XV-XV of Fig. I~
DESCRIPT~ON OF THE PREFER~ED EMBODIMENTS
Tle multi-zoned reaction vessel of the invention is hereinafter described particularly with respect to the measurement or detection of analytes of biological liquids such as serum, plasma or whole blood. Liquids such as industrial liquids are also analyzable using the vessel of this invention. In addition, the vessel can be ~sed to interact a liquid with a reagent for many other purposes.
I have discovered that a reaction vessel wherein intended liquid transpor~ is provided by capillary attrac-tion, can be constructed to temporarily stop the liquid transport, and thereafter reactivate the transpor~, with-out alterin~ the given volume of liquid needed for reac-tions in the vessel. Such a vessel is particularly useful in conducting immunoassays and the analysis of whole blood.
In the embodiment of Figs. 1 and 2, a reaction vessel 20 is provided, comprising means defining a first zone 22 fluidly connected by passageway 60 to means defin-ing an adjacent zone 24 adapted to receive liquid flowfrom zone 22. In accordance with one aspect of the inven-tion, the zone-defining means comprise a first member 44 and a cover member 42 disposed in superposed relationship by spacer member 30, Fig. 2. Members 42 and 44 provide two opposed liquid transport surfaces 26 and 28, respec-tively, and spacer member 30 provides sidewall surfaces 32 and 34 and end walls 36 and 38, Fig. l. Sidewall surfaces 26 and 28 and walls 36 and 38 are shown as solid lines in Fig. l Eor clarity, such as they would appear if cover member 42 were transparent. Surfaces 26 and 28, Fig, 2, are space~ apart a distance h in zone 22~ and distance h' in zone 24, both of which are selected to provide capillary flow of liquid. To insure capillary flow for liquids such as whole blood or blood serum, distance h does not exceed about 1 mm. To complete the transfer of all the liquid into zone 24 following breach of passageway 60, and to retain liquld in zone 24, distance h' is preferably less than distance h. Specifically, a reduction in the spacing distance of at least 25% is useful to induce substantially complete liquid transfer to zone 24 within a time compatible with the analyses of choice. Most preferably, h is 125 microns or less to minimize the amount of liquid required for the reaction within the vessel, and h' is 94 microns or less. The selection of distance h' to be sign;ficantly less than h requires that the areas of surfaces 26 and 28 of zone 24 be relatively enlarged to insure that all of the liquid of zone 22 will be accommodated in zone 24.
Additional ~ones, not shown, lacking such capil-lary spacing and therefore not adapted to receive liquid flow can be fluidly connected to zone 24, for example, adjacent to end wall 38.
To permit introduction of liquid into zone 22, a liquid inlet aperture 46 is provided in one of members 42 and 44, preferably 42, thereby defining a locus of liquid introduction. A quantity of liquid is to be deposited at aperture 46, preferably in drop form.
The size of aperture 46 is selected to insure that the volume of liquid introduced will contact both surfaces 26 and 28, to initiate capillary transport of a liquid meniscus through zone 22. If a 10 ~1 of liquid is the amount to be introduced for purposes of the in-tended test, aperture 46 is preferably about 1.0 mm to about 5.0 mm in diameter. Alterna~ively, aperture 46 is shaped to have cornered sidewalls, not shown, so as to have the shape of, for example, a hexagon instead of a circle to insure ~ore positive movement of the liquid into the aperture.
To insure proper wave front shape and prevent air L~ 3 ~L

entrspment, aperture 46 is located prefera~ly at a point closer to end wall 36 than to sidewall surfaces 32 or 34, Fig. l. Most preferably, it is located on the bisector line 48 between s;dewall surfaces 32 and 34.
The reagent (not shown) with which the liquid is to interact in zone 22 is preferably coated or otherwise bonded, such as by a chemical bond, onto any one of the exposed surfaces of zone 22, e.g., surfaces 26, 2~, 32, 34 or wall 36. The reagent can be soluble or insoluble in the liquid to be reacted.
To permit air to be expelled from %ones 22 and 24 ahead of an advancing liquid meniscus, apertures 50 are provided, preferably through member 42 in the vicini~y of zone 24. Most preferably apertures 50 are located adja-cent to the intersection formed by sidewall surface 32with end wall 38, and sidewall surface 3~1 with end wall 3~. Such locations permit full capillary flow in zone 24 with a minimum amount of resistance.
Members 42 and 44 are secured to spacer member 30 20 by any conventional means, for example, a water-insol-uble adhesive.
In accordance with an importan~ aspect of the invention, to control the liquid meniscus by temporarily stopping it from flowing from zone 22 to zone 24, a nar-rowed passageway is formed by the surfaces defining thezones. In the embodiment of Figs. l and 2, a gradually narrowed passageway 60 comprises sidewall surfaces 32 and 34 shaped to form sharply defined opposed edges 62 located between the two zones and spaced a distance "d". The con-vergence of surfaces 32 and 34, provided by decreasedspacing sl, occurs preferably over at least the last 35%
of the flow of liquid within zone 22, measured from aper-ture 46 to passageway 60.
It is not certain what interaction bet~een the 35 meniscus and the sidewall surfaces creates the phenomenon of meniscus stoppage. Tests have shown that the use of gradually, rather than abruptly, converging sidewall sur-q i~

faces is preferred, together with edges 62 being limited to a radius of curvature no greater than about 0.02 cm.
~y this construction, edges 62 act as an energy barrier to capillary fl~w ~f liquid and specifically to flow of meniscus 68. The passageway does not, however, block flow of gas since passageway 60 is free of material that would block gas flow.
The convergence of sidewall surfaces 32 and 34 in zone 22 need not be at a constant rate. Alternatively, vessel 20 îs useful if sidewall surfaces 32 and 34 con-verge at an increasing rate as flow proceeds to passageway 60 (phantom lines for zone 22, Fig. 1). In such an alter-nate embodiment, the sidewall surfaces are concave and provide an increased volume for zone 22.
The stoppage of liquid flow at edges 62 is designed to occur when most, and preferably substantially all of the liyuid, is within zone 22. That is, the volume of the liquid is selected to be consistent with the volume of zone 22. Only a negli~ible amount, if any, shown as portion L, should project out of the reaction vessel, as it is desired in at least immunoassay uses of the vessel that all of the predictable volume of liquid react in zone 22 with a immuno-reagent. For this reason, at least for tests involving constant liquid volumes, at least cover member 42 is preferably substantially rlgid, in both zones 22 and 24. As used herein, a "substantially rigid member"
is a member having, when freely spanning a distance e~ual to the width or length of either zone of the element, and with atmospheric pressure on both sides of the member, a 3 free-span deflection, hereinafter "sag", that does not exceed about 0.025 mm. In zone 22, if member ~2 has any appreciable sag, one or both of the following could occur: The sagging portion could act as a "meniscus con-trol means", prematurely stopping the meniscus before passageway 60 is reached. Alternatively, the sagging por-tion could cause air entrapment in the vicinity thereof.
In either case, the entire volume of added liquid would 3~

not flow in~o zone 22 and the interac~ion with the reagent of tha~ zone would not occur to the desired extent.
Cover member 42 is preferably rigid at zone 24 because sagging por~ions could again form air en~rapment.
Such air entrap~ent could prevent transfer of all of the liquid from the first zorle to the second zone.
Although it is not critical to an understanding of the invention, it ls believed that shape of the menis CU8 as it approaches the passageway is a~ least partially 10 responsible for the stoppage of the meniscus. lf the men-iscus has the shapes shown ~s 68', angled to the sidewall surfaces as passageway 60 is approached, ~ig. 1, it does stop a~ the passageway, in the absence of applied, extern ally generated pressures.
ln contrast, Fig. 4, sidewall surfaces modified SG as to abruptly alter the spacing s' a~ the control passageway, e.g.~ by ~he use oI a wall 67 extending generally perpendlcularly from sidewall surface 32, will not stop the capillary liquid flow. (In this example, 20 aperture 69 has spacing D comparable to dlstance "d" of passageway 60 previously described.) Instead of being stopped, flow of liquid through aperture 69 contlnues at a retarded rate as is described in U.S. Patent 4,310,399 issued January 12, 1982, entltled "Liquid Transport Devlce 25 Containing Means for Delaying Capillary ~low". The meniscus 68" tends to have a shape that is roughly parallel to wall 67 in this instance, ln the viclnity of aperture 69.
Sidewall surfaces 32 and 34 preferably extend, 30 ~ig- 1, from edges 62 into zone 24 with a configuration that aids in the emp~ying o~ all the liquid into zone 24, Flg. 3, once flow starts past edges 62. Specifically~ the sidewall surfaces preferably diverg~ into zone 24 from passageway 60 with a constantly increasing spacing s 35 ~ig. 1, or at an increasing rate (shown in phantom as convexly curved walls).
The pressure ~P~ Fig. 3, needed to push the liquid meniscus past edges 62 is an lnverse function of L~ 3 the spacing d. Accordingly, that spacing is selected to provide sufficient stoppa~e of the meniscus 68 without requiring the use of excessive external pressuresO A
preferred va~ue of d is about ().04 cm. ~f distance h' is about 0. n3 crn, the distance from aperture 46 to passageway 60 is about 0.9 cm, and d is about 0.04 cm, the pu]se of pressure necessary to push a serum meniscus past the passageway is about ~00 dynes/cm2. Lesser values of d will require greater pressures to overcoMe the stoppage of flow at passageway 60-A further ;mportant aspect of this invention isthat it is the increased capillary attraction provided by the reduced capillary spacing h' of zone 24, Fig. 2, that provides the comple~ion of the transfer of liquid from zone 22 to zone 24, rather than the displaced air created by the externally generated pressure. The advantage is that such capillary attraction is effective to provide complete transfer, even if the volume of liquid in zone 22 deviates slightly from the expected volume. The use of pressure displacement to displace a given volume of liquid equal to the displaced air volume would not be readily adjustable for such liquid volume deviations. Therefore, the ~P pressure applied to push the meniscus into zone 24 is only an impulse the duration of which is by itself insufficient to transfer all the liquid. A duration of between about 1 and about 10 milliseconds is sufficient in many cases to push the meniscus 68 into zone 24, where the increased capillary attraction completes the transfer.
To minimize shear stresses as liquid is forced to flow through passageway 60, the length 1 of passageway 60, Fig. 2, is minimized. Specifically, by providing sharp edges 62 with a negligible length in the direction of fluid flow therepast, preferably no greater than about 0.03 cm, the shear stresses that occur when liquid flows through passageway 60 are minimized. Such minimized shear stresses permit the processing of whole blood, as is described hereinafter.
The preferred gas used to form the pulse of f~

pressure ~P is air, as is described herein. It will be appreciated that other gases are also useful, most pref-erably those ~hat are iner~ relative ~o the liquid and the reagents used.
Although an immiscible liquid is useful also as a medium for deliverin~ the pulse of pressure, gas is the preferred medium inasmuch as an immiscible liquid could move ahead of the reaction liquid and prevent complete transfer of the desired liquid to the second zone.
The behavior of liquid introduced into zone 22 at aperture 46 will be apparent from the preceding. That is, distance h is such that liquid introduced into zone 22 without any significant external pressure will flow withln and through the zone between transport surfaces 26 and 23 by capillary attraction. A characteristic of passageway 60 is that the advancing liquid meniscus 68 stops at edge 62 even in those instances in which minor amounts of liquid L remain above aperture 46, Fi~. 2. The liquid remains temporarily stopped at edges ~2 while any ~as gen-erated in zone 22 is free to flow into zone 24. There-after, an externally generated air pressure impulse ~P, Fig. 3, is applied to the li~uid in zone 22. The pressure is applied by any conventional pressurizer, not shown.
The energy barrier of edges 62 is overcome by this applied air pressure, and the liquid of zone 22 flows, arrow 69, into zone 24. As noted, the applied pressure is preferably insufficient to cause, itself alone, a com-pletion of the transfer of liquid from zone 22 to zone 24. In accord with well-known principles of capillarity, the smaller spacing of distance h' insures that the liquid will preferentially flow into zone 24 until zone 22 is empty, and further that the liquid will not return to zone 22. Air is pushed out apertures 50 ahead of the advancing meniscus. The meniscus stops (at 70, Fig. 3) when it reaches those apertures. Additional processing then takes place in zone 24, for example, a reaction with additional reagents, or a measurement of analyte in the liquid by an appropria~e scan, arrow 72, usin~ electromagnetic radia-tion Lhat passes through either member 44, as shown, or member 42 if exposed from Above (not shown). If the direction of scan is as indicated by arrow 72, member 44 is preferably transparent, at least in the area of ~one
2~1. If zone 22 is scanned also, the entire member 44 is preferably transparent.
Measurements conducted in the second zone are selected to be compatible with the rea~ent and the interaction provided in the first zone. ~seful examples Of measurements include radiometric detection of a radio-metrically detectable change. Specifically, a photometer or a fluorimeter is useful to reflectively detect the pro-duction of a dye density or to detect a fluoroscence, respectively. Also, measurements using the detection of radioactive labels are possible with this vessel.
Specific useful materials for members 42, 44, and spacer member 30 include materials such as cellulose triacetate and materials, such as polypropylene, polystyrene, polyethylene, styrene-butadiene and ABS
plastic, that are coated with a surfactant. These materials are sufficiently rigid at the desired thick-nesses, for example, from about 0.018 to about 0.04 cm, for cover member 42. In addition, a flexible material such as a 25-micron polyethylene sheet is useful to pro-vide the liquid transport surface of the cover member ifit is laminated to a sheet selected from one of the rigid materials noted above.
As an alternative to the use of a reduced value of h', liquid can be preferentially and permanently emptied from æone 22 into zone ~4 by the use of a sur factant soluble in the liquid, that is coated on either or both of surfaces 26 and 28. The surfaces in this instance are formed from relatively non-wettable materials such as polystyrene. As used herein, "non-wettable" and "wettable" represent a condition best measured by the con-tact angle between ~he liquid and the surface in ques-tion. More specifically, a surface is generally con-sidered non-wettable if the contact angle is greater than ~ 3~

or equal to 90 and wettabl~ if it is less than 90. The coating is applied to both zones 22 and 24 (not shown).
Useful surfactants include, for example, a nonylphenoxy polyglycidol surfactant obtainable under the trade name "Olin lOG" from Olin. As long as the surfactant remains on the surfaces, the liquid will wet the hydrophobic surface and zone 22 can be filled. However, the surfactant immediately dissolves from the walls of zone 22 when wetted. Therefore, after the liquid flows into zone 24, a thin film residue of liquid apparently forms and evaporates, and surfaces 26 and 28 of zone 22 revert back to being essentially non-wettable. Thust the liquid cannot return to zone 22. In such an embodiment, any distance h' eEfective to insure capillary flow into zone 24, such as 1 mm or less, is useful regardless of its relationship to distance h of ~one 22. That is, the trailing meniscus (not shown) of liquid exiting zone 22 "sees" a surface condition that is essentially non-wettable. In contrast, the advancing meniscus 68 readily wets the surfactant-coated surfaces. The result is an imbalance in driving forces, causing the liquid to empty from zone 22 into zone 24. Furthermore, the hydrophobic nature of the surfaces of now-emptied zone 22 is a sufficient energy barrier to return flow.
The previous embodiments are based on the assump~
tion that once the liquid has moved into the second zone, no significant amount of the liquid should remain in or flow back to the first zone, such as by a return flow through the meniscus control passageway. However9 in some 30 instances it is permissible and desirable for liquid to remain in or return to the first zone, for example if the first zone of the reaction vessel is to be used to carry out an additional reaction on reaction products produced in the second zone. For this embodiment, distances h and 35 h' between the opposed transport surfaces of the two zones are preferably equal (not shown) and preferably no water-soluble surfactant is used. An impulse of pressure, if of short duration as for the previous embodiments, will only move the liquid part-way into the ~econd zone where it can react with a reagent in that zone. An additional reagent i5 immobilized in the first zone, selected to react only with the reaction products produced by the reagent of the second zone. As each reaction takes place in its respective zone, a concentration gradient is created that induces diffusion of the necessary ingredient or reaction product to the zone where that reaction takes place.
Either of the opposed surfaces 26 and 28 can be 10 nominally smooth, as shown in the embodiment of Fig. 2, or they can be provided with a regular pattern of grooves, Fig. 5. Parts similar to those previously described bear the same reference numeral, to which the distinguishing suffix "a" has been attached. Thus, vessel 20a comprises 15 a cover member 42a, support member 44a, and spacer member 30a defining a first zone 22a, a second zone not shown, and a meniscus control means as described above. Under-surface 26a, however, is provided with grooves spaced apart a regular distance by sawtooth ridges 80. Pref-20 erably the ridges are mutually parallel and extend per-pendicularly to the bisector line between the sidewalls.
If surface 28a is optionally ~rooved, not shown, the grooves preferably extend at a positive angle to the grooves and ridges 80 of surface 26a in the manner taught by U.SO Patent No. 4,233,029, issued November 11, 1980.
It is not essential that the spacing of surfaces 26 and 28 be capillary precisely at the location of aper-ture 46, as i5 demonstrated in the embodiment of Fig. 6.
Parts similar to those previously described bear the same reference numeral to which the distinguishing suffix "b"
is applied. The vessel 20b comprises member 42b and 44b, member 42b having an inlet aperture 46b permitting liquid introduction into zone 22b. However, unlike previous embodiments, spacing H at the aperture 46b is optionally non-capillary, surfaces 26b and 28b being shaped to gradu-ally converge to a capillary spacing h at the portion of
3~

zone 22b contiguous with the meniscus control passageway (not shown). No sharp edges are present to create a barrier to Flow. This embodiment uses injection metering of sufficient pressure to move liquid into that portion of zone 22b wherein the spacing is distance h and capillary action takes over to maintain flow towards the meniscus control passageway. The injection pressure is selected such that the pressure behind the meniscus when it reaches the meniscus co~trol passageway, is significantly less than the ~P pressure necessary to overcome the energy barrier of that passageway. End wall 36b is preferably sloped in this embodiment, to deflect incoming liquid to insure that the liquid continues, under the injection pressure, to advance to the point where capillary flow begins.
This embodiment also demonstrates that the spacer member, here shoulder 30b, can be an integral part of member 44b, as shown, or of member 42b.
The meniscus control means between the two zones need not be defined by the sidewall surfaces. In the embodiment of Fig. 7, it is provided by the spaced-apart transport surfaces of the zones. Parts similar to those previously described bear the same reference numeral to which the distinguishing suffix "c" is applied. Thus, vessel 20c comprises a cover member 42c and support member 44c that provide opposed transpor~ surfaces 26c and 28c, preferably formed from hydrophobic materials coated with a water-soluble surfactant as described above. ~ones 22c and 24c are provided, separated by a meniscus control 3 means in the form of a narrowed passageway SOc, as described in the previous embodiment. Howeverl in this embodiment, the sharply defined edges 62c of the passageway 60c comprise opposed ridges in the opposed transport surfaces 26c and ?8c that extend from sidewall surface 32c to the opposite sidewall surface. The shape of the opposed transport surfaces preferably is such that the advancing meniscus, as it approaches passageway 62c, extends generally perpendicularly, dashed lines 90, to the surfaces forming edges 62c. This meniscus shape appar-ently ensures that the edges 62c act as an energy barrier to further ~eni.ccus flow. Most preferably; those surfaces are shaped so that distance " h" " between these surfaces is reduced at an inc~easing rate in the vicinity of passageway 60c to create opposed concavities immediately adjacent the ed~es 62c. As in previous embodiments, the length of passageway 60c in the direction of flow preferably cloes not exceed about 0.03 cm.
It will be appreciated that, because the meniscus control means comprise features of opposed transport sur-Faces 26c and 28c, the spacing between the sidewall sur-faces is of no consequence to the stoppage of the menis-cus. Such spacing can be selected to be constant or variable, as desired.
Preferably, zone 24c features opposed surfaces 92, here portions of surfaces 26c and 28c, that extend into that zone from passageway 60c at a separation distance that increases at a constant or at an increasin~
rate. Such a rate of separation helps to ;nsure that once the liquid meniscus moves into zone 24b, all the liquid flows into æone 24b.
In the embodiments of Figs. 8 and 9, the meniscus control means features a sudden increase in the capillary spacing between the opposed transport surfaces, rather than a narrowing of the spacing. Parts similar to those previously described bear the same reference numeral to which the distinguishing suffixes "d" and "e," respec-tively, are appended.
Thus, vessels 20d and 20e are constructed in thesame manner as the vessel of Fig. 1, with opposed trans-port surfaces 26d and 28d, or 26e and 28e, respectively.
These surfaces together with sidewall surfaces such as surface 32d form first and second zones 22d and 24d, or 3 22e and ~4e, respectively, separated by the meniscus con-troi means. However, in the embodiment of Flg. 8, the meniscus control means 60d comprises a channel 100 in at least one of the opposed surfaces, here surface 26d, having a depth h2 and a width w2 that are sufficient to create an energy barr;er ~o meniscus flow, and ~hus to stop flow. Specifically, the energy barrier comprises ~he sharp edge 101 created in surface 26d by the sudden depth h2 of channel 100. The channel extends the full width between the zones, in order to be effective. Mos~ pref-erably, the sharp edge of the energy barrier is created by a channel having a dep~h h that is at least about 0.02 mm greater than th spacing hd between surfaces 26d and 28d, and a width w that is greater than or equal to hd. As in the embodiment of Fig. 1, distance hd' of zone 2~d is significantly less than distance hd of zonP
22d, and the total volumes of the two zones are adjusted to be generally equal. The radius of curvature of edge 101 preferably does no~ exceed about 0.02 cm.
In the embodiment of Fig~ 9, the meniscus control means comprises a pair of opposed channels 100' and 100", each with a depth h3 and h4, respectively, and a width w3. To create the energy barrier to capillary flow, both edges lOle and lOle' are sharp as before and the com-bined depth (h3 + h4) is preferably at least about 0.015 mm greater than the distance he. Width w3 need not have the same relationship to he as w2 has to hd in the embodiment of Fig. 8. Preferably w3 is at least 25 microns. Distance h ' is at least 25% less than h .
A total depth (he + h3 + h4) that is e greater than a capillary spacing is also useful. The externally generated pressure is selected to be large enough to move meniscus ~8e into contact with zone 24e. A
pressure of at least 800 dynes/cm2 is useful for channels 100' and 100" having depths such that h3 + h4 ~ he total about 0.415 mm, and a common width w3 equaling 25 microns.
The aforedescribed reaction ~essels are useful to provide a variety of interactions in the first zone be-tween a reagent and material of the liquid, followed by analysis in the second zone. As used herein, a "reagent"
means any substance that is interactive with a material, such as an analyte, of the liquid, or a decomposition or reaction product of that material. "Interaction" and "interactive" refer to chemical reactions, catalytic activity such as enzymatic reactions, immunological reac-tions, or any other form of chemical or physical inter-action that can result in the production o~ a useful result in the second zone. Preferred are those inter-actions that permit analysis o~ the material of the liquid. Hi~hly preferred are binding reactions in which a reagent immobilized in the first zone binds to at least a portion of the material of the liquid, thus retaining that bound portion in the first zone. This binding reaction occurs whether the materials to be bound aré labeled or unlabeled. If the vessel is to be used as an immunoassay device, as described hereafter, both labeled analo~ and unlabeled analyte comprise the material that binds, in a compe~ing fashion, to the reagent. If the vessel is to be used as a test device for whole blood, also as described hereafter, the materials that bind are the cells of whole blood, which need not be labeled for purposes of the test.
Preferably the reagent is immobilized on one or both of the sidewall surfaces or the opposed capillary transport surfaces of the first zone of the vessel of the invention. Alternatively, and particularly in those instances in which a relatively high volume of material is to interact with the immobilized reagent, the reagent is immobilized on fillers such as beads as described in European Patent Application No. 13,156, published July 4, 1980. The beads in turn are disposed in the first zone and secured in place, for example by the use of a water-insoluble adhesive of the type described in the aforesaid 3 European Patent Application No. 13,156. In yet another embodiment (not shown) the beads are loosely disposed in the first 20ne, having a size that prevents them from passing through passageway 60. In this embodlment, dis-tance "d" is substantially less than distance "h."
~ s used herein, "immobillzed" refers to a con-dition of immovable adherence created by any mechanism, such as chemical bonding, that is sufficient ~o withstand the pressures and stresses generated within the zones 3~-during use of the vessel or test device. A reagent is immob;lized to one vf the surfaces of the transport zone, or to inert fillers ;n the zone, if that reagent is bonded or adsorbed directly thereto, or if it is bonded via an interrnediate, water-insoluble material that is itself secured to the zone.
Hi~hly preferred reagents include those which produce immuno-reactions, such as antibodies or antigens, hereinafter "immunogens." The material of the liquid in such a case is the corresponding immunogen, that is, ~he antigen or antibody, respectively. Any immuno-reaction is detectable using the vessel of the invention, by the procedure hereinafter described. Immunological reagen~s, hereinafter "immunogen reagents", are preferably immobilized by being adsorbed or covalently bonded by any conventional procedure to any of the surfaces of the first ~one, or to beads that are secured to the first zone. One example of a useful procedure for covalently bonding an 2 immunogen reagent is as follows:
A polyacrylamide is selected to which the immunogen reagent is to be secured. This is either the material of the walls of the zone, or polyacrylamide beads adhered to the walls by a water-insoluble adhesive. The polyacrylamide in turn is partially hydrolyzed or hydrazi-nolyzed to permit covalent bonding by the antibodies.
Details are described, for example, in U.S. Patent No.
3,853,987.
Indirect covalent bonding is also useful, wherein a coupling agent is used having groups that will coval-ently bond with both the immunogen reagent and the walls of the zone (or beads secured to the zone). For example, covalent bonding of an immunogen reagent to ceramic beads is possible using the intermediate coupling agents described in U.S. Patent No. 3,6~2,761.
~he selection of an immunogen as the reagent per-mits immunoassays to be conducted using the vessel of the invention. The embodiment of Figs. 10-12 is illustrative of a vessel adapted to such a use. Parts similar to those previously described bear the same reference numeral to which the distinguishing suffix "f" is applied~ Thus, vessel 20f is a test device comprising first and second zones 22f and 24f, formed by cover member 42f and support member 44f, separated by spacer member 30f, Fi~. 11. The two zones are separated but f]uidly connected by narrowed passageway 60f as the meniscus control means. As shown, passageway 60f features two opposed edges 62f in sidewall surfaces 32f and 34f. Aperture 46f in member 42~ permits liquid introduction and apertures 50f permit air venting.
In this embodiment, to minimize air entrapment, sidewall surfaces 32f and 34f are joined to form an angle beta (~) where end wall 36 would otherwise be, and aperture ~6f is on the bisector of angle ~, Fig. 10. Angle ~
is preferably between about 7 and 75O, and most pref-erably, 60. Wall surfaces 32f and 34f curvilinearly connect wi~h passageway 60f to prevent the advancing wavefront from encountering edge discontinuities before encountering edges 62f. As passageway 60f is neared, surfaces 32f and 34f converge at an increasing rate, consistent with the absence of edge discontinuities other than edge 62f. If angle ~ is about 60, then the angle of convergence ~, Fig. 10, is preferably about 120.
Most preferably, an immunogen reagent for a par-ticular complementary immunogen is immobilized in the first zone, in the form, for example, of a coating 110 bonded to surface 28f of zone 22f, Fig. 11. Preferably~
surface 26f bears a wat~r-soluble surfactant (not shown) as discussed for previous embodiments. A known amount of the analog having an appropriate label is added to æone 22f either as an additional pre-applied reagent or as a liquid added with, to, or after the unknown sample. It will be appreciated that care is taken not to admix the analog and the immunogen reagent before adding the immunogen of the liquid to be assayed. The label i5 any detectable species, for example, an enzyme, a fluorescent species, or a radioactive species, chemically or physically linked (such as by adsorption) to the antigen 3:~

or antibody. For example, a fluorescent species 5uch as fluorescein is covalently bonded ~o ~n antigenO In a pre-ferred embodiment, a polymeric latex bead is "loaded" with a fluorescent rare earth chelate, preferably a europium or terbium chelate. The resultant rare earth chelate- loaded latex bead is employed as a fluorescent label to which the analog of choice is physically adsorbed or covalently bonded. These la~ex polymer beads preferably have an average diameter of from about OoOl to about 0.2 micron and are "loaded" with up to about 7.5 weight percent of the rare earth chelate. Becau~e of the large number of rare earth chelate molecules which can be loaded into a single lat~x bead, the resultant label is highly fluorescent and provides immuno-fluorescence exhibiting -5 excellent sensitivity. A highly preferred analog is one employing a fluorescent, rare earth chelate-loaded poly-meric latex bead as described in Frank and Sundber~, European Patent Application No. 002,963, published 11/7/79 While the liquid and meniscus 68f are retained in the ~- first zone by the meniscus control means, Fig. 12a, the analog and the immunogen to be assayed compete for binding to the immunogen reagent which is immobili7ed in the first zone ~2f of the vessel. After an appropriate length of eime~ for example, 5 to 15 minutes, a pulse of pressure '5 such as 800 dynes/cm2 is applied to force the liquid to empty from the first zone into the second, Fig. 12b, carrying immunogen and analog that have not become bound to the immunogen reagent. Useful methods of measurement to determine the concentration of immunogen which are then 3 employed include: (A) detecting the unbound analog which has flowed into the second zone, and/or (B) detecting the analog which remains bound to the immobilized immunogen reagent in the first zone. In either method, the amount of immunogen in the liquid sample is determined based on the detected concentration of analog in accordance with conventional immunological techniques. Such techniques are set forth in European Patent Application 13,156, published July 9, 1980.
It has been determined that the ionic bond formed in an immuno-reaction i5 sufficient to withstand the shear stress generated by ~he pulse of pressure used to force plasma, for example, having a viscosity of 2.4 centipoise, to flow from zone 22f into zone 24f past passageway 60f.
That is, under less than the best conditions, the shear stress likely to occur can be shown to be about 2 X
l0-14 nt/molecule. The energy bond strength can be lO shown to be about 10 lO nt/molecule, more than enough to resist the stress.
An advantage of vessel 22f is tha~ the concen-tration determined by the measurement made in zone 24f of free analog, can be checked by measuring ~he bound analog 15 in zone 22f.
The vessel of the invention containing the immobilized form of the reagent in the first zone has other uses in addition to immunolog;cal assays. Such immobilized reagents permit the vessel of the invention to 20 be used as a test device for whole blood. In such an embodiment, the immobilized reagent is selected to be a red cell-agglutinating reagent. Such a reagent a~tracts or binds substantially all the red blood cells of whole blood added to the device, leaving only the plasma and i~s 25 contained analyte material free to flow into the second zone when an externally generated pulse of pressure is delivered to the liquid of the first zone in the manner described above. The necessary reagents for analyzing the analyte material of the plasma are contained in the second 30 zone.
Useful examples of such reagents for immobilizing the red cells include agglutinating reagents such as positively charged polymers, e.g., polybrene; lectins;
high molecular weight dextrans; and phytohemagglutinin as 35 described in U.SO Patent No. 3,146,163, and U.S. Patent No. 3,902,964. The last-noted materials are proteinaceous, and as such are subject to bonding to appropriate surfaces, such as polyacrylamide, by the procedures described above. Thus, agglu~inating agents are readily immobilized to the wall surfaces of the first zone and/or to beads secured to the first zone.
The embodiment of F'ig. 13 illustrates a vessel constructed in the above manner as a test device for the measu~ement of an analyte of whole blood. Parts similar to those previously described bear the same reference numeral to which the distinguishing suffix "g" is applied. Thus, vessel 20g comprises opposed members 42g and 44g and spacer member 30g, forming flrst and second zones 22g and 24g with a meniscus control means in the form of a narrowed passageway 60g between them, as before. Apertures 46g and 50g are formed as before for introduction of liquid and for air venting. Also as in the case of the device of Fig. 11, a reagent coating llOg is applied to at least one of the walls of zone 22g directly, or to beads adhered wi~hin the zone, not shown.
Surface 26g of both zones 22g and 26g preferably bears a water-soluble wetting agent or surfactant (not shown), and the material of members 42g, 44g, and 30g is selected to be relatively non-wetting. The beads, if used, preferably occupy less than 50% of the volume of zone 22g. In this case, the reagent is an agglutinating agent such as phytohemagglutinin, immobilized as described above.
Alternatively, vessel 20g is useful if the vent apertures are formed in spacer member 30g, as shown by the dashed lines 50g' of Fig. 13. Preferably, such apertures are formed by notching the top of spacer member 30g.
To permit the analysis of the no~-separated plasma as it enters zone 24g in response to the externally generat~d pressure, an analyte detection element 120 is provided in or adjacent to member 44g in zone 24g, spaced from surface 26g. Preferably the detection element comprises one or more detection reagent layers 122 having a variety of binder compositions and a variety of detection reagents~ For example, gelatin, cellulose acetate, polyvinyl alcohol, agarose and the like 3~

are useful binders, the degree of hydrophilicity of the layer being dependent upon the material selected.
Additional layers are useful disposed above layer 122 to provide a variety of chemistries or functions. If used, these additional layers provide additional detection reagents, or filtering, registration and/or mordanting functions, such as are described itl U.S. Patent No.
4,0~i2,335, issued on August 16, 1977.
As used herein, "detection reagcnt" means a material that is capable of interaction with an analyte, a precursor of an analyte, a decomposition product of an analyte, or an intermediate of an analyte, to ultimately produce a detectable response. Useful detection elements in many instances include a first detection reagent that produces from the analyte an intermediate or a decomposi-tion product, and 3 second detection reagent, labeled "indicator" because of its function, that is responsive to the intermediate or decomposition product to produce said change. Useful detection reagents also include preformed, radiometrically detectable species that are caused by the analyte of choice to move out of a radiometrically opaque portion or layer of the detection element, into a radio-metrically transparent portion or layer, such as a regis-tration layer which can be layer 122 in contact with mem-ber 44g.
The noted interaction between a detection reagent and the analyte therefore includes chemical reactions, catalytic activity as in the formation of an enzyme-sub-strate complex, or any other form of chemical or physicalinteraction, including physical displacement, that can produce ultimately a detectable response in the test ele-ment. The assay method is designed to produce a response signal that is predictably related to the amount of analyte that is present.
The preferred detection element is designed to measure radiometric responses, produced by impinging electromagnetic energy on the element. As is well known, radiometric detection includes both colorimetric and fluorimetric detection, depending upon the detection reagents selected as the indicator.
The detection element 120 is adaptive to a variety of different analy~es. Preferably, the assays are all oxygen-independent, as the flow of liquid into the zor~e 24g ~ends to seal off detection element 120 from any additional oxygen. I'ypical analytes which can be tested include total protein, bilirubin and the like. Useful detectlon reagents and binder or vehicle compositions for, e.g., layer 122 and any additional layers of the element include those described in, respectively, for those analytes, U.S. Patent Nos. 4,132,528, issued on January 2, 1979; and ~,069,016 or 4,069,017, issued on January 17, 1978. Detection element 120 is also useful to test for other analytes.
The method of using vessel 20g will be apparent from the preceding discussion. A quantity of whole blood, for example, a drop, is added to zone 22g via aperture 46g, and the meniscus flows up to edges 62g of passageway 60g, where it stops. Coating llOg comprising a red cell-agglutinating reagent immobilizes the red cells while the liquid remains in zone 22g. After an appropriate length of time, such as 10 minutes, the plasma is separable from the cells by applying an impulse of pressure, such as a pressure of about 300 dynes/cm2, to aperture 46g. The plasma flows into zone 24g and into detection element 120. After an incubation period of up to about five to ten minutes, a radiometric signal is generated which is detected in element 120 by a sui~ably calibrated radio-meter.
More than two zones are useful in the vessel of the invention, a meniscus control means preferably being disposed between each pair of adjacent zones. Parts similar to those previously described bear the same reference numeral, to which the distinguishing suffix "h"
is added. Thus, Figs. 14 and 15, vessel 20h comprises opposed members 42h and 44h, spaced apart by spacer member 30h. Aperture 46h permits access of liquid to a first ?
-28~
zone 22h having a coating llOh on surface 28h, Fig. 15.
Coating llOh comprises a cell-agglutinating reagent bonded to surface 28h, as descri~ed for the previous embodiment.
Surface 26h is preferably coated with a water-soluble surfactant and members L2h, 44h and 30h are relatively non-wetting, as before. Passageway 60h comprising opposed, sharply-derined sidewall edges 62h, Fig. 15, confines the whole blood within zone 22h to allow the red blood cells to become bound.
Unlike the previous embodiments, vessel 20h has a total of three zones, Fig. 15, of approximately equal volume, the two additional zones being intermediate ~one 160 and analysis zone 24h disposed downstream from zone 22h. Each of the zones is separated from but fluidly connected to the upstream zone by a meniscus control means. Such control means comprise passageway 60h for zone 160 and passageway 16~ for ~one 24h. Preferably, passageway 162 features opposed edges 163 extending from transport surfaces 26h and 2~h, Fig. 15. This arrangement avoids the necessity of gradually increasing the spacing of the spacer member sidewall surfaces 32h and 34h, Fig.
14, that confine the detection element 120h. Zone 160 preferably includes a coating 164, such as on surface 28h, Fig. 15, of a detection reagent additional to those present in detection element 120h located in zone 24h. As shown, detection element 120h is a multi-layered element the layers of which are stacked against the flow of liquid into zone 24h. In a preferred form, detection element 120h comprises at least layer 122h, and optionally, a detection reagent layèr 12~ and a barrier composition layer 124. The barrier composition is uniformly permeable to a gas such as NH3, but is substantially impermeable, over the time of the test, to interferents such as are carried by water. Because of this arrangement, vent apertures 50h preferably are located in spacer member 30h.
A preferred use of vessel 20h is as a test device for plasma ammonia alone, or for plasma ammonia follo~ed by plasma creatinine. Coating 164 for these uses com-prises a buffer selected to maintain a ph o~ about 9.0 ln the plasma, to release dissolved ammoni~. A preferred buffer is a mix~ure of tris buffer~ comprising tris-~hydroxymethylaminomethane)~ and KH2PO4. Indieator layer 122h of element 120h comprises an indicator respon-sive to ammonia that changes color ln proportion to the amount of NH3 gas that flows into layer 122h from zone 160 while the plasma is being retained in zone 160. For example, bromophenol blue is usleful as the indicator.
Alternatively~ element 120h further includes a detection reagent, preferably in l~yer 126, that decom-poses creatinine into Nh3 gas, and the de~cribed barrier composition, prefersbly in layer 124, that allows the NH3 but not the liquid of the plasma to permeate. Use-ful compositions for layers 124 and 126, as well as layer 122h 5 are described in commonly-owned U.S. Patent No.
4~276,377 issued June 30, 1981.
The immedlately described alternative construc-tion of vessel 20h and de~ection element 120h i6 used first to test for plasma ammonia, ~nd then optionally to test for plasma creatinine. After the plasma is forced into zone 160, coating 164 ser~es to release plasma am-monia as N~3 gas, which gas flows into zone 24h while the plasma is stopped at passagewsy 162. The ~3 per-meates indicator layer 122h of detection element 120h tointeract to produce a detectable color change. After the color change that is proportional to the plasma ammonia is detec~ed, the plasma is analyzed for creatinine content.
For this, a second impulse of air pressure is applied at aperture 46h, this time to push the liquid meni6cus past passageway 162. The liquid then flow~ into zone 24h and into detectlon el~ment 120h. The additional ~3 gener-ated from the decomposition of creatinine is detectable by the same lndica~or u~ed for the ammonia.

9 ~ 3 ~

To ~se vessel 40h as a test device only for plasma ammonia, the second impulse of pressure is simply omitted.
Yet ano~her alternative embodiment of the inven-tion, not shown, comprises the device of Fig. 15 whereinzone 22h is omitted and a previously obtained plasma is placed via an inlet aperture, such as aperture 46h, directly into zone 160. The procedure for the sequential detection of plasma ammonia and/or creatinine is followed as descrlbed above.
The invention has been described in detail with particular reference to preferred embodiments thereof, but it will be understood that variations and modifications can be effected within the spirit and scope of the inven-tion.

3o

Claims (28)

WHAT IS CLAIMED IS:
1. In a reaction vessel comprising a first zone, a second zone adapted to receive liquid flow from the first zone, at least one of said zones containing a reagent capable of interacting with a material of a liquid introduced into said first zone, said zones comprising a first member, a cover member, and spacing means for disposing said first member and said cover member in superposed relationship, said first and said cover members having opposed surfaces pro-viding transport of liquid introduced between them, inlet means permitting the introduction of the liquid into said first zone, and a passageway fluidly connecting said zones;
the improvement wherein said opposed surfaces are spaced apart a distance that is effective to induce capil-lary flow of said introduced liquid at least in the por-tion of said first zone contiguous to said passageway, and in said second zone, and wherein said passageway includes meniscus control means for temporarily stopping the liquid meniscus from proceeding by capillary attraction into said second zone from said first zone, said control means being con-figured to permit the liquid to flow into said second zone only when an externally generated pressure is applied to the liquid in an amount sufficient to push the liquid meniscus into said second zone.
2. In a reaction vessel comprising a first zone, a second zone adapted to receive the liquid from the first zone, at least one of said zones containing a reagent capable of interacting with a material of a liquid introduced into said first zone, said zones comprising a first member, a cover member, and means for disposing said first member and said cover member in superposed relationship, said first and said cover members having opposed surfaces providing transport of liquid introduced between them, inlet means permitting the introduction of the liquid into said first zone, and a passageway fluidly connecting said zones;
the improvement wherein said opposed surfaces are spaced apart a distance effective to induce capillary flow of said introduced liquid at least in the portion of said first zone contiguous to said passageway, and in said second zone, and wherein said passageway includes meniscus control means for temporarily stopping the liquid meniscus from proceeding by capillary attraction into said second zone from said first zone, said control means being con-figured to permit the liquid to pass into said second zone only when an externally generated pressure is applied to the liquid in an amount sufficient to push the liquid men-iscus into said second zone, said distance of said second zone being less than said distance of said first zone by an amount effective to preferentially attract said liquid, in response to said push of the liquid by the pressure, into said second zone from said first zone and to confine the attracted liquid within the second zone.
3. In a reaction vessel comprising a first zone, a second zone adapted to receive the liquid from the first zone, at least one of said zones containing a reagent capable of interacting with a material of a liquid introduced into said first zone, said zones comprising a first member, a cover member, and means for disposing said first member and said cover member in superposed relationship, said first and said cover members having opposed surfaces providing transport of liquid introduced between them, inlet means permitting the introduction of the liquid into said first zone, and a passageway fluidly connecting said zones;
the improvement wherein said opposed surfaces are spaced apart a distance effective to induce capillary flow of said introduced liquid at least in the portion of said first zone contiguous to said passageway, and in said second zone, at least one of said two surfaces comprising, in both of said zones, a relatively non-wettable material coated with a surfactant soluble in the liquid and capable of making said surfaces wettable by the liquid, and wherein said passageway includes meniscus control means for temporarily stopping the liquid meniscus from proceeding by capillary attraction into said second zone from said first zone, said control means being con figured to permit the liquid to pass into said second zone only then an externally generated pressure is applied to the liquid in an amount sufficient to push the liquid men-iscus into said second zone.
4. A vessel as defined in claim 1 and further including sidewall surfaces cooperating with said two surfaces to define said zones, said sidewall surfaces forming in said passageway an energy barrier to meniscus flow such that the liquid meniscus stops at said passage-way.
5. A vessel as defined in claim 1, further including sidewall surfaces in said second zone adjacent to said passageway, which diverge from said pas-sageway into said second zone at a constant or at an in-creasing rate.
6. A vessel as defined in claim 2 and further includ-ing sidewall surfaces in said second zone adjacent to said passageway, which diverge from said passageway into said second zone at a constant or at an increasing rate.
7. A vessel as defined in claim 3 and further including sidewall surfaces in said second zone adjacent to said passageway, which diverge from said passageway into said second zone at a constant or at an increasing rate.
8. A vessel as defined in claims 5, 6 or 7 wherein the rate of divergence between said sidewall surfaces of said second zone increases with distance from said passageway.
9. A vessell as defined in claim 1, 2 or 3 wherein said meniscus control means comprises a pair of opposed ridges in said two opposed surfaces that provide a reduction in said spaced-apart distance.
10. A vessel as defined in claim 1, 2, or 3, wherein said distance is reduced between said two opposed surfaces at an increased rate as said meniscus control means is approached from said inlet means.
11. A vessel as defined in claim 1, 2, or 3, wherein said meniscus control means comprises a channel in at least one of said two opposed surfaces having a depth and width sufficient to stop the meniscus from flowing into said second zone.
12. A vessel as defined in claim 1, 2, or 3, wherein said meniscus control means comprises A channel in at least one of said two opposed surfaces having a depth of at least about 0.02 mm greater than said spaced apart distance between said two opposed surfaces.
13. A vessel as defined in claim 1, 2, or 3, wherein said meniscus control means comprises two opposed channels, one in each of said opposed surfaces, having a combined depth that is at least 0.015 mm greater than said spaced-apart distance between said two opposed surfaces.
14. A vessel as defined in claim 1, 2, or 3, wherein at least said cover member is substantially rigid.
15. A vessel as defined in claim 1, 2, or 3, wherein said distance is effective to induce capillary flow of said introduced liquid from said inlet means to said passagewey.
16. A vessel as defined in claim 1, 2, or 3, and further including sidewall surfaces cooperating with said two surfaces to define said transport zones, said sidewall surfaces and said two surfaces forming said passageway with a length in the direction of liquid flow therethrough that is no greater than about 0.03 cm.
17. A vessel as defined in claim 1, 2, or 3, and further including in at least one of said zones a reagent that interacts with said liquid.
18. A vessel as defined in claim 1, 2, or 3, wherein said energy barrier comprises opposed edges in said sidewall surfaces.
19. A vessel as defined in claim 1, wherein said first zone reagent is capable of binding with a material of the liquid and with a known, labeled amount of said material, and wherein said other of said zones is adapted for detection of labeled material, whereby said vessel is a test device for an immunoassay.
20. A device as defined in claim 19 wherein said material is an immunogen present in a biological liquid, and said reagent is the immunogen complement.
21. A device as defined in claim 20 wherein both of said zones are adapted for detection of said labeled material.
22. A device as defined in claim 19 and further including sidewall surfaces cooperating with said cover member and said first member to define said zones, said sidewall surfaces forming in said passageway an energy barrier to meniscus flow such that the meniscus of the liquid stops at said passageway.
23. A device as defined in claim 22 wherein said passageway comprises opposed edges in said sidewall surfaces.
24. A device as defined in claim 19 wherein said meniscus control means comprises h pair of opposed ridges in said cover member and said first member that provide a reduction in said spaced-apart distance.
25. A device as defined in claim 19 wherein said meniscus control means comprises a channel in at least one of said cover member and said first member having a depth and width sufficient to stop the meniscus from flowing into said other zone.
26 . A vessel as defined in claim 1, wherein said first zone reagent is a cell-agglutinating reagent immov-ably adhered to at least one of i) said members and ii) said spacing means;
said second zone being adapted to receive plasma from said first zone and containing a detection element including a least one detection reagent specific to the analysis of an analyte of the plasma.
27. A vessel as defined in claim 26 end further including a third zone disposed between said first end second zones and fluidly connected thereto by two of said meniscus control means.
28. A vessel as defined in claim 27 wherein said detection element comprises detection reagents suf-ficient to generate a color change proportional to the amount of plasma ammonia as well as the amount of plasma creatinine that are present in the whole blood.
CA000382977A 1981-01-28 1981-07-31 Multi-zoned reaction vessel having pressure- actuatable control means between zones Expired CA1189431A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US229,038 1981-01-28
US06/229,038 US4426451A (en) 1981-01-28 1981-01-28 Multi-zoned reaction vessel having pressure-actuatable control means between zones

Publications (1)

Publication Number Publication Date
CA1189431A true CA1189431A (en) 1985-06-25

Family

ID=22859590

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000382977A Expired CA1189431A (en) 1981-01-28 1981-07-31 Multi-zoned reaction vessel having pressure- actuatable control means between zones

Country Status (5)

Country Link
US (1) US4426451A (en)
EP (1) EP0057110B2 (en)
JP (1) JPS57156028A (en)
CA (1) CA1189431A (en)
DE (1) DE3263066D1 (en)

Families Citing this family (381)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663296A (en) * 1980-05-05 1987-05-05 Hoffmann-La Roche Inc. Multicuvette rotor for analyzer
DE3134611A1 (en) * 1981-09-01 1983-03-10 Boehringer Mannheim Gmbh, 6800 Mannheim METHOD FOR CARRYING OUT ANALYTICAL PROVISIONS AND MEANS SUITABLE FOR THIS
GB8306353D0 (en) * 1983-03-08 1983-04-13 Stuart J F B Monitoring of drug levels
DE3441149A1 (en) * 1984-11-10 1986-05-15 Merck Patent Gmbh, 6100 Darmstadt METHOD FOR SEVERAL BLOOD SEPARATION
EP0293519A1 (en) * 1987-06-03 1988-12-07 James F. Brown Capillary flow control
US4676274A (en) * 1985-02-28 1987-06-30 Brown James F Capillary flow control
DE3508427A1 (en) * 1985-03-09 1986-09-11 Merck Patent Gmbh, 6100 Darmstadt AGENT AND METHOD FOR SEPARATING PLASMA OR SERUM FROM WHOLE BLOOD
JPS61278761A (en) * 1985-06-04 1986-12-09 Fuji Photo Film Co Ltd Integral type multi-layered analyzing element for analyzing ammonia forming substrate
US4756884A (en) * 1985-08-05 1988-07-12 Biotrack, Inc. Capillary flow device
US4761381A (en) * 1985-09-18 1988-08-02 Miles Inc. Volume metering capillary gap device for applying a liquid sample onto a reactive surface
CA1292176C (en) * 1985-09-18 1991-11-19 Joel M. Blatt Volume metering capillary gap device for applying a liquid sample onto a reactive surface
JPH0616045B2 (en) * 1985-10-24 1994-03-02 ヒユ−・ブイ・コツチンガム Liquid particle reagent agglutination slide
FR2589239B1 (en) * 1985-10-24 1989-10-20 Cottingham Hugh AGGLUTINOGRAPHIC REACTION CHAMBER
WO1987006003A1 (en) * 1986-03-25 1987-10-08 P B Diagnostic Systems, Inc. Biological diagnostic device
US4906439A (en) * 1986-03-25 1990-03-06 Pb Diagnostic Systems, Inc. Biological diagnostic device and method of use
EP0245994A3 (en) * 1986-04-28 1988-07-06 Ici Australia Limited Method and apparatus for reaction
US5120504A (en) * 1986-07-14 1992-06-09 Hybritech Incorporated Apparatus for immunoassays with vent chennels in the container side wall
US5135719A (en) * 1986-10-29 1992-08-04 Biotrack, Inc. Blood separation device comprising a filter and a capillary flow pathway exiting the filter
US4753776A (en) * 1986-10-29 1988-06-28 Biotrack, Inc. Blood separation device comprising a filter and a capillary flow pathway exiting the filter
DE3745131C2 (en) * 1986-11-18 2000-06-29 Hugh V Cottingham Agglutinographic chamber for immunochemical liquid reagents
US4775515A (en) * 1986-11-18 1988-10-04 Cottingham Hugh V Agglutinographic slide
DE3706718A1 (en) * 1987-03-02 1988-09-15 Boehringer Mannheim Gmbh DEVICE FOR CARRYING OUT A HETEROGENEOUS REACTION
US4918025A (en) * 1987-03-03 1990-04-17 Pb Diagnostic Systems, Inc. Self contained immunoassay element
US5047206A (en) * 1987-03-11 1991-09-10 Wayne State University Reagent test strip
US4849340A (en) * 1987-04-03 1989-07-18 Cardiovascular Diagnostics, Inc. Reaction system element and method for performing prothrombin time assay
DE3721237A1 (en) * 1987-06-27 1989-01-05 Boehringer Mannheim Gmbh DIAGNOSTIC TEST CARRIER AND METHOD FOR THE PRODUCTION THEREOF
ES2049254T3 (en) * 1987-08-27 1994-04-16 Biotrack Inc APPARATUS AND PROCEDURE FOR THE DILUTION AND MIXING OF LIQUID SAMPLES.
US5077017A (en) * 1987-11-05 1991-12-31 Biotrack, Inc. Integrated serial dilution and mixing cartridge
US4810653A (en) * 1987-11-23 1989-03-07 Eastman Kodak Company Cuvette with non-flexing thermally conductive wall
DK163194C (en) * 1988-12-22 1992-06-22 Radiometer As METHOD OF PHOTOMETRIC IN VITRO DETERMINING A BLOOD GAS PARAMETER IN A BLOOD TEST
US5564419A (en) * 1987-11-25 1996-10-15 Radiometer A/S Method of photometric in vitro determination of the content of oxygen in a blood sample
US5209904A (en) * 1987-12-23 1993-05-11 Abbott Laboratories Agglutination reaction device utilizing selectively impregnated porous material
US4979402A (en) * 1988-01-27 1990-12-25 Ryan Will G Aliquoting of serial liquid samples
US5503803A (en) * 1988-03-28 1996-04-02 Conception Technologies, Inc. Miniaturized biological assembly
US5200152A (en) * 1988-03-28 1993-04-06 Cytonix Corporation Miniaturized biological assembly
US5051237A (en) * 1988-06-23 1991-09-24 P B Diagnostic Systems, Inc. Liquid transport system
US5340539A (en) * 1989-03-16 1994-08-23 Chemtrak, Inc. Non-instrumented cholesterol assay
US4957582A (en) * 1989-03-16 1990-09-18 Eastman Kodak Company Capillary transport zone coated with adhesive
US5437979A (en) * 1989-07-24 1995-08-01 Beckman Instruments, Inc. Solid phase system for sequential reactions
US5620657A (en) * 1989-11-27 1997-04-15 Behringwerke Ag Device and method for completing a fluidic circuit
AU642444B2 (en) * 1989-11-30 1993-10-21 Mochida Pharmaceutical Co., Ltd. Reaction vessel
DE3941150A1 (en) * 1989-12-13 1991-06-20 Boehringer Mannheim Gmbh METHOD FOR DETERMINING AN ANALYTE
US5066465A (en) * 1989-12-27 1991-11-19 Olympus Optical Co., Ltd. Reaction apparatus
US5188968A (en) * 1989-12-28 1993-02-23 Olympus Optical Co., Ltd. Method and reaction kit for agglutination detection
DE69019326T2 (en) * 1989-12-28 1995-11-09 Olympus Optical Co Reaction kit.
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
DE4015589A1 (en) * 1990-05-15 1991-11-21 Boehringer Mannheim Gmbh DEVICE AND THE USE THEREOF FOR SEPARATING PLASMA FROM WHOLE BLOOD
US5212065A (en) * 1990-10-25 1993-05-18 International Diagnostic Systems, Corp. Rapid assay device
US5230866A (en) * 1991-03-01 1993-07-27 Biotrack, Inc. Capillary stop-flow junction having improved stability against accidental fluid flow
US5998220A (en) 1991-05-29 1999-12-07 Beckman Coulter, Inc. Opposable-element assay devices, kits, and methods employing them
US6168956B1 (en) 1991-05-29 2001-01-02 Beckman Coulter, Inc. Multiple component chromatographic assay device
US5877028A (en) 1991-05-29 1999-03-02 Smithkline Diagnostics, Inc. Immunochromatographic assay device
US5726010A (en) * 1991-07-31 1998-03-10 Idexx Laboratories, Inc. Reversible flow chromatographic binding assay
US6007999A (en) * 1991-07-31 1999-12-28 Idexx Laboratories, Inc. Reversible flow chromatographic binding assay
WO1993018398A1 (en) * 1992-03-10 1993-09-16 Quidel Corporation Red blood cell separation means for specific binding assays
JP3382632B2 (en) * 1992-03-13 2003-03-04 オリンパス光学工業株式会社 Method for measuring biological substance and reaction vessel used for the method
US5223219A (en) * 1992-04-10 1993-06-29 Biotrack, Inc. Analytical cartridge and system for detecting analytes in liquid samples
US5222808A (en) * 1992-04-10 1993-06-29 Biotrack, Inc. Capillary mixing device
US5458852A (en) * 1992-05-21 1995-10-17 Biosite Diagnostics, Inc. Diagnostic devices for the controlled movement of reagents without membranes
US6019944A (en) * 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6143576A (en) * 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US6156270A (en) * 1992-05-21 2000-12-05 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US7524456B1 (en) 1992-05-21 2009-04-28 Biosite Incorporated Diagnostic devices for the controlled movement of reagents without membranes
US6767510B1 (en) * 1992-05-21 2004-07-27 Biosite, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6905882B2 (en) * 1992-05-21 2005-06-14 Biosite, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US5503985A (en) * 1993-02-18 1996-04-02 Cathey; Cheryl A. Disposable device for diagnostic assays
US5798215A (en) * 1993-02-18 1998-08-25 Biocircuits Corporation Device for use in analyte detection assays
US5652148A (en) * 1993-04-20 1997-07-29 Actimed Laboratories, Inc. Method and apparatus for red blood cell separation
US5385847A (en) * 1993-12-02 1995-01-31 Miles Inc. Method for the determination of urinary protein and creatinine
FI940823A0 (en) * 1994-02-22 1994-02-22 Orion Yhtymae Oy Analyzer cuvette Foer turbidimetric and nephelometric test of the helix
CA2143365A1 (en) * 1994-03-14 1995-09-15 Hugh V. Cottingham Nucleic acid amplification method and apparatus
US5725831A (en) * 1994-03-14 1998-03-10 Becton Dickinson And Company Nucleic acid amplification apparatus
US5609824A (en) * 1994-07-13 1997-03-11 I-Stat Corporation Methods and apparatus for rapid equilibration of dissolved gas composition
US5460782A (en) * 1994-07-18 1995-10-24 Safe-Tec Clinical Products, Inc. Automatic filling micropipette with dispensing means
US5627041A (en) * 1994-09-02 1997-05-06 Biometric Imaging, Inc. Disposable cartridge for an assay of a biological sample
US5603351A (en) * 1995-06-07 1997-02-18 David Sarnoff Research Center, Inc. Method and system for inhibiting cross-contamination in fluids of combinatorial chemistry device
US5846396A (en) * 1994-11-10 1998-12-08 Sarnoff Corporation Liquid distribution system
US5554536A (en) * 1995-01-05 1996-09-10 Millipore Investment Holdings Limited Biological analysis device having improved contamination prevention
JPH11505327A (en) 1995-05-09 1999-05-18 スミスクライン ダイアグノスティックス インコーポレイテッド Apparatus and method for separating cellular components of blood from liquid portion of blood
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US20020022261A1 (en) * 1995-06-29 2002-02-21 Anderson Rolfe C. Miniaturized genetic analysis systems and methods
US20050100946A1 (en) * 1995-06-29 2005-05-12 Affymetrix, Inc. Integrated nucleic acid diagnostic device and method for in-situ confocal microscopy
US6168948B1 (en) 1995-06-29 2001-01-02 Affymetrix, Inc. Miniaturized genetic analysis systems and methods
US20020068357A1 (en) * 1995-09-28 2002-06-06 Mathies Richard A. Miniaturized integrated nucleic acid processing and analysis device and method
US6033544A (en) * 1996-10-11 2000-03-07 Sarnoff Corporation Liquid distribution system
US6143248A (en) * 1996-08-12 2000-11-07 Gamera Bioscience Corp. Capillary microvalve
US6113855A (en) * 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US6083761A (en) * 1996-12-02 2000-07-04 Glaxo Wellcome Inc. Method and apparatus for transferring and combining reagents
US5879951A (en) * 1997-01-29 1999-03-09 Smithkline Diagnostics, Inc. Opposable-element assay device employing unidirectional flow
US5939252A (en) * 1997-05-09 1999-08-17 Lennon; Donald J. Detachable-element assay device
WO1998054563A1 (en) * 1997-05-29 1998-12-03 Angelo Joseph P D Estimation of active infection by helicobacter pylori
US5989840A (en) * 1997-05-29 1999-11-23 Americare International Diagnostics, Inc. Estimation of active infection by heliobacter pylori
US6090251A (en) * 1997-06-06 2000-07-18 Caliper Technologies, Inc. Microfabricated structures for facilitating fluid introduction into microfluidic devices
US5992820A (en) * 1997-11-19 1999-11-30 Sarnoff Corporation Flow control in microfluidics devices by controlled bubble formation
US6036924A (en) 1997-12-04 2000-03-14 Hewlett-Packard Company Cassette of lancet cartridges for sampling blood
US8071384B2 (en) 1997-12-22 2011-12-06 Roche Diagnostics Operations, Inc. Control and calibration solutions and methods for their use
AU758407B2 (en) 1997-12-24 2003-03-20 Cepheid Integrated fluid manipulation cartridge
US6184040B1 (en) 1998-02-12 2001-02-06 Polaroid Corporation Diagnostic assay system and method
US6117396A (en) * 1998-02-18 2000-09-12 Orchid Biocomputer, Inc. Device for delivering defined volumes
WO1999061892A1 (en) * 1998-03-06 1999-12-02 Angelo Joseph P D Estimation of active infection by helicobacter pylori
DE59905743D1 (en) * 1998-03-11 2003-07-03 Steag Microparts Gmbh SAMPLE CARRIER
US6391005B1 (en) 1998-03-30 2002-05-21 Agilent Technologies, Inc. Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
GB9808836D0 (en) * 1998-04-27 1998-06-24 Amersham Pharm Biotech Uk Ltd Microfabricated apparatus for cell based assays
US20040202579A1 (en) * 1998-05-08 2004-10-14 Anders Larsson Microfluidic device
GB9809943D0 (en) * 1998-05-08 1998-07-08 Amersham Pharm Biotech Ab Microfluidic device
US6780617B2 (en) 2000-12-29 2004-08-24 Chen & Chen, Llc Sample processing device and method
US7799521B2 (en) * 1998-06-24 2010-09-21 Chen & Chen, Llc Thermal cycling
CA2301153C (en) 1998-06-24 2008-08-26 Chen & Chen, Llc Fluid sample testing system
US6830934B1 (en) * 1999-06-15 2004-12-14 Lifescan, Inc. Microdroplet dispensing for a medical diagnostic device
US6261519B1 (en) 1998-07-20 2001-07-17 Lifescan, Inc. Medical diagnostic device with enough-sample indicator
US6084660A (en) * 1998-07-20 2000-07-04 Lifescan, Inc. Initiation of an analytical measurement in blood
US6521182B1 (en) * 1998-07-20 2003-02-18 Lifescan, Inc. Fluidic device for medical diagnostics
US6601613B2 (en) 1998-10-13 2003-08-05 Biomicro Systems, Inc. Fluid circuit components based upon passive fluid dynamics
JP2002527250A (en) 1998-10-13 2002-08-27 バイオマイクロ システムズ インコーポレイテッド Fluid circuit components based on passive hydrodynamics
US6591852B1 (en) 1998-10-13 2003-07-15 Biomicro Systems, Inc. Fluid circuit components based upon passive fluid dynamics
US6637463B1 (en) 1998-10-13 2003-10-28 Biomicro Systems, Inc. Multi-channel microfluidic system design with balanced fluid flow distribution
US6495373B1 (en) 1998-10-14 2002-12-17 Polaroid Corporation Method and apparatus for performing diagnostic tests
US6331715B1 (en) 1998-10-14 2001-12-18 Polaroid Corporation Diagnostic assay system and method having a luminescent readout signal
US6555060B1 (en) 1998-10-14 2003-04-29 Polaroid Corporation Apparatus for performing diagnostic testing
US7914994B2 (en) 1998-12-24 2011-03-29 Cepheid Method for separating an analyte from a sample
US6887693B2 (en) 1998-12-24 2005-05-03 Cepheid Device and method for lysing cells, spores, or microorganisms
US6431476B1 (en) 1999-12-21 2002-08-13 Cepheid Apparatus and method for rapid ultrasonic disruption of cells or viruses
US6328930B1 (en) 1999-02-11 2001-12-11 Polaroid Corporation Apparatus for performing diagnostic testing
US6296702B1 (en) * 1999-03-15 2001-10-02 Pe Corporation (Ny) Apparatus and method for spotting a substrate
US6551842B1 (en) 1999-03-26 2003-04-22 Idexx Laboratories, Inc. Method and device for detecting analytes in fluids
US6511814B1 (en) * 1999-03-26 2003-01-28 Idexx Laboratories, Inc. Method and device for detecting analytes in fluids
US6375817B1 (en) 1999-04-16 2002-04-23 Perseptive Biosystems, Inc. Apparatus and methods for sample analysis
US6605475B1 (en) 1999-04-16 2003-08-12 Perspective Biosystems, Inc. Apparatus and method for sample delivery
US6937330B2 (en) 1999-04-23 2005-08-30 Ppd Biomarker Discovery Sciences, Llc Disposable optical cuvette cartridge with low fluorescence material
US6485690B1 (en) 1999-05-27 2002-11-26 Orchid Biosciences, Inc. Multiple fluid sample processor and system
US8815521B2 (en) 2000-05-30 2014-08-26 Cepheid Apparatus and method for cell disruption
WO2000073413A2 (en) 1999-05-28 2000-12-07 Cepheid Apparatus and method for cell disruption
US9073053B2 (en) 1999-05-28 2015-07-07 Cepheid Apparatus and method for cell disruption
US20040200909A1 (en) * 1999-05-28 2004-10-14 Cepheid Apparatus and method for cell disruption
CA2375197A1 (en) * 1999-06-08 2000-12-14 Biomicro Systems, Inc. Laser ablation of doped fluorocarbon materials and applications thereof
US6193471B1 (en) * 1999-06-30 2001-02-27 Perseptive Biosystems, Inc. Pneumatic control of formation and transport of small volume liquid samples
US6687395B1 (en) * 1999-07-21 2004-02-03 Surromed, Inc. System for microvolume laser scanning cytometry
US20050103624A1 (en) 1999-10-04 2005-05-19 Bhullar Raghbir S. Biosensor and method of making
WO2001026813A2 (en) 1999-10-08 2001-04-19 Micronics, Inc. Microfluidics without electrically of mechanically operated pumps
US6319719B1 (en) 1999-10-28 2001-11-20 Roche Diagnostics Corporation Capillary hematocrit separation structure and method
CN1632553A (en) * 1999-11-15 2005-06-29 松下电器产业株式会社 Biosensor, method of forming thin-film electrode, and method and apparatus for quantitative determination
US6451264B1 (en) 2000-01-28 2002-09-17 Roche Diagnostics Corporation Fluid flow control in curved capillary channels
US6406672B1 (en) 2000-01-28 2002-06-18 Roche Diagnostics Plasma retention structure providing internal flow
US6403037B1 (en) * 2000-02-04 2002-06-11 Cepheid Reaction vessel and temperature control system
US6908593B1 (en) * 2000-03-31 2005-06-21 Lifescan, Inc. Capillary flow control in a fluidic diagnostic device
US6488827B1 (en) * 2000-03-31 2002-12-03 Lifescan, Inc. Capillary flow control in a medical diagnostic device
US6561208B1 (en) 2000-04-14 2003-05-13 Nanostream, Inc. Fluidic impedances in microfluidic system
SE0001790D0 (en) * 2000-05-12 2000-05-12 Aamic Ab Hydrophobic barrier
WO2001089696A2 (en) * 2000-05-24 2001-11-29 Micronics, Inc. Microfluidic concentration gradient loop
PL365675A1 (en) * 2000-07-31 2005-01-10 Lifescan, Inc. Method and apparatus for detecting the presence of a fluid on a test strip
US6615856B2 (en) * 2000-08-04 2003-09-09 Biomicro Systems, Inc. Remote valving for microfluidic flow control
US6652814B1 (en) 2000-08-11 2003-11-25 Lifescan, Inc. Strip holder for use in a test strip meter
US6866822B1 (en) 2000-08-11 2005-03-15 Lifescan, Inc. Gimbaled bladder actuator for use with test strips
US6867049B1 (en) * 2000-09-27 2005-03-15 Becton, Dickinson And Company Method for obtaining increased particle concentration for optical examination
US6641782B1 (en) 2000-11-15 2003-11-04 Polaroid Corporation Apparatus for performing diagnostic testing
US8641644B2 (en) * 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
DE10057832C1 (en) * 2000-11-21 2002-02-21 Hartmann Paul Ag Blood analysis device has syringe mounted in casing, annular mounting carrying needles mounted behind test strip and being swiveled so that needle can be pushed through strip and aperture in casing to take blood sample
SE0004351D0 (en) * 2000-11-27 2000-11-27 Helen Andersson System and method for time-controlled liquid handling for reactions and processes in a microfluidic flow cell system
US6787761B2 (en) * 2000-11-27 2004-09-07 Surromed, Inc. Median filter for liquid chromatography-mass spectrometry data
US20020095260A1 (en) * 2000-11-28 2002-07-18 Surromed, Inc. Methods for efficiently mining broad data sets for biological markers
US7232510B2 (en) * 2000-11-30 2007-06-19 Matsushita Electric Industrial Co., Ltd. Biosensor, measuring instrument for biosensor, and method of quantifying substrate
US7087389B2 (en) 2001-02-09 2006-08-08 Council Of Scientific & Industrial Research Highly cost-effective analytical device for performing immunoassays with ultra high sensitivity
US6949377B2 (en) * 2001-03-05 2005-09-27 Ho Winston Z Chemiluminescence-based microfluidic biochip
US20020127740A1 (en) * 2001-03-06 2002-09-12 Ho Winston Z. Quantitative microfluidic biochip and method of use
JP4148778B2 (en) * 2001-03-09 2008-09-10 バイオミクロ システムズ インコーポレイティッド Microfluidic interface equipment with arrays
WO2002099410A1 (en) * 2001-06-04 2002-12-12 Aclara Biosciences, Inc. Sensor device and method for indicating oxygen consumption
US7318912B2 (en) * 2001-06-07 2008-01-15 Nanostream, Inc. Microfluidic systems and methods for combining discrete fluid volumes
US7749174B2 (en) * 2001-06-12 2010-07-06 Pelikan Technologies, Inc. Method and apparatus for lancet launching device intergrated onto a blood-sampling cartridge
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
EP1404234B1 (en) 2001-06-12 2011-02-09 Pelikan Technologies Inc. Apparatus for improving success rate of blood yield from a fingerstick
US7981056B2 (en) * 2002-04-19 2011-07-19 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
DE60234598D1 (en) * 2001-06-12 2010-01-14 Pelikan Technologies Inc SELF-OPTIMIZING LANZET DEVICE WITH ADAPTANT FOR TEMPORAL FLUCTUATIONS OF SKIN PROPERTIES
US9226699B2 (en) * 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
ATE485766T1 (en) 2001-06-12 2010-11-15 Pelikan Technologies Inc ELECTRICAL ACTUATING ELEMENT FOR A LANCET
US7025774B2 (en) 2001-06-12 2006-04-11 Pelikan Technologies, Inc. Tissue penetration device
CA2448681C (en) 2001-06-12 2014-09-09 Pelikan Technologies, Inc. Integrated blood sampling analysis system with multi-use sampling module
US8337419B2 (en) 2002-04-19 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7682318B2 (en) 2001-06-12 2010-03-23 Pelikan Technologies, Inc. Blood sampling apparatus and method
US20070100255A1 (en) * 2002-04-19 2007-05-03 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US20030015425A1 (en) * 2001-06-20 2003-01-23 Coventor Inc. Microfluidic system including a virtual wall fluid interface port for interfacing fluids with the microfluidic system
US7179423B2 (en) * 2001-06-20 2007-02-20 Cytonome, Inc. Microfluidic system including a virtual wall fluid interface port for interfacing fluids with the microfluidic system
US20020195343A1 (en) * 2001-06-20 2002-12-26 Coventor, Inc. Microfabricated separation device employing a virtual wall for interfacing fluids
US20020197733A1 (en) * 2001-06-20 2002-12-26 Coventor, Inc. Microfluidic system including a virtual wall fluid interface port for interfacing fluids with the microfluidic system
US7211442B2 (en) * 2001-06-20 2007-05-01 Cytonome, Inc. Microfluidic system including a virtual wall fluid interface port for interfacing fluids with the microfluidic system
US7077152B2 (en) * 2001-07-07 2006-07-18 Nanostream, Inc. Microfluidic metering systems and methods
US7776608B2 (en) * 2001-07-09 2010-08-17 Bayer Healthcare Llc Volume meter testing device and method of use
US7270959B2 (en) 2001-07-25 2007-09-18 Oakville Hong Kong Company Limited Specimen collection container
US7300633B2 (en) * 2001-07-25 2007-11-27 Oakville Hong Kong Company Limited Specimen collection container
US6873915B2 (en) * 2001-08-24 2005-03-29 Surromed, Inc. Peak selection in multidimensional data
JP4513085B2 (en) 2001-09-11 2010-07-28 アイキューム インク Sample container
US20030078739A1 (en) * 2001-10-05 2003-04-24 Surromed, Inc. Feature list extraction from data sets such as spectra
US7344894B2 (en) 2001-10-16 2008-03-18 Agilent Technologies, Inc. Thermal regulation of fluidic samples within a diagnostic cartridge
US7537731B2 (en) * 2001-10-19 2009-05-26 Panasonic Corporation Specific binding analysis device
US7767437B2 (en) * 2001-11-02 2010-08-03 Genefluidics, Inc. System for detection of a component in a liquid
US6997343B2 (en) 2001-11-14 2006-02-14 Hypoguard Limited Sensor dispensing device
US7098041B2 (en) 2001-12-11 2006-08-29 Kimberly-Clark Worldwide, Inc. Methods to view and analyze the results from diffraction-based diagnostics
US7102752B2 (en) * 2001-12-11 2006-09-05 Kimberly-Clark Worldwide, Inc. Systems to view and analyze the results from diffraction-based diagnostics
US20030119203A1 (en) * 2001-12-24 2003-06-26 Kimberly-Clark Worldwide, Inc. Lateral flow assay devices and methods for conducting assays
US8367013B2 (en) * 2001-12-24 2013-02-05 Kimberly-Clark Worldwide, Inc. Reading device, method, and system for conducting lateral flow assays
US20030180814A1 (en) * 2002-03-21 2003-09-25 Alastair Hodges Direct immunosensor assay
US20060134713A1 (en) * 2002-03-21 2006-06-22 Lifescan, Inc. Biosensor apparatus and methods of use
JP2004003976A (en) * 2002-04-05 2004-01-08 Matsushita Electric Ind Co Ltd Method for analyzing specific bond, and device used for the same
US6976590B2 (en) 2002-06-24 2005-12-20 Cytonome, Inc. Method and apparatus for sorting particles
US20070065808A1 (en) * 2002-04-17 2007-03-22 Cytonome, Inc. Method and apparatus for sorting particles
US6877528B2 (en) * 2002-04-17 2005-04-12 Cytonome, Inc. Microfluidic system including a bubble valve for regulating fluid flow through a microchannel
US9943847B2 (en) 2002-04-17 2018-04-17 Cytonome/St, Llc Microfluidic system including a bubble valve for regulating fluid flow through a microchannel
US6808075B2 (en) 2002-04-17 2004-10-26 Cytonome, Inc. Method and apparatus for sorting particles
US7175642B2 (en) 2002-04-19 2007-02-13 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US7374544B2 (en) 2002-04-19 2008-05-20 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8221334B2 (en) * 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7229458B2 (en) 2002-04-19 2007-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8360992B2 (en) * 2002-04-19 2013-01-29 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7244265B2 (en) * 2002-04-19 2007-07-17 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7563232B2 (en) 2002-04-19 2009-07-21 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7582099B2 (en) 2002-04-19 2009-09-01 Pelikan Technologies, Inc Method and apparatus for penetrating tissue
WO2003088824A2 (en) 2002-04-19 2003-10-30 Pelikan Technologies, Inc. Device and method for variable speed lancet
US9795334B2 (en) * 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7648468B2 (en) * 2002-04-19 2010-01-19 Pelikon Technologies, Inc. Method and apparatus for penetrating tissue
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7371247B2 (en) 2002-04-19 2008-05-13 Pelikan Technologies, Inc Method and apparatus for penetrating tissue
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8784335B2 (en) * 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US7331931B2 (en) 2002-04-19 2008-02-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7291117B2 (en) * 2002-04-19 2007-11-06 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US20070142748A1 (en) * 2002-04-19 2007-06-21 Ajay Deshmukh Tissue penetration device
US7485128B2 (en) 2002-04-19 2009-02-03 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7976476B2 (en) 2002-04-19 2011-07-12 Pelikan Technologies, Inc. Device and method for variable speed lancet
US7524293B2 (en) * 2002-04-19 2009-04-28 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8702624B2 (en) * 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US7141058B2 (en) 2002-04-19 2006-11-28 Pelikan Technologies, Inc. Method and apparatus for a body fluid sampling device using illumination
US7297122B2 (en) * 2002-04-19 2007-11-20 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7892185B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US7909778B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7226461B2 (en) 2002-04-19 2007-06-05 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7410468B2 (en) * 2002-04-19 2008-08-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8267870B2 (en) * 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US7717863B2 (en) * 2002-04-19 2010-05-18 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7232451B2 (en) 2002-04-19 2007-06-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7491178B2 (en) * 2002-04-19 2009-02-17 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7901362B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7892183B2 (en) * 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
AU2003239409A1 (en) * 2002-05-09 2003-11-11 Surromed, Inc. Methods for time-alignment of liquid chromatography-mass spectrometry data
US20040067481A1 (en) * 2002-06-12 2004-04-08 Leslie Leonard Thermal sensor for fluid detection
US7250095B2 (en) 2002-07-11 2007-07-31 Hypoguard Limited Enzyme electrodes and method of manufacture
US7604775B2 (en) * 2002-08-12 2009-10-20 Bayer Healthcare Llc Fluid collecting and monitoring device
US7314763B2 (en) * 2002-08-27 2008-01-01 Kimberly-Clark Worldwide, Inc. Fluidics-based assay devices
US7285424B2 (en) * 2002-08-27 2007-10-23 Kimberly-Clark Worldwide, Inc. Membrane-based assay devices
US7432105B2 (en) * 2002-08-27 2008-10-07 Kimberly-Clark Worldwide, Inc. Self-calibration system for a magnetic binding assay
DE10244775A1 (en) 2002-09-26 2004-04-08 Roche Diagnostics Gmbh Capillary sensor analysis system
US6939450B2 (en) * 2002-10-08 2005-09-06 Abbott Laboratories Device having a flow channel
EP1419818B1 (en) * 2002-11-14 2013-10-30 Boehringer Ingelheim microParts GmbH Device for sequential transport of liquids by capillary forces
US7781172B2 (en) * 2003-11-21 2010-08-24 Kimberly-Clark Worldwide, Inc. Method for extending the dynamic detection range of assay devices
US20040106190A1 (en) * 2002-12-03 2004-06-03 Kimberly-Clark Worldwide, Inc. Flow-through assay devices
EP1578286A4 (en) * 2002-12-13 2009-01-14 Pelikan Technologies Inc Method and apparatus for measuring analytes
US7247500B2 (en) * 2002-12-19 2007-07-24 Kimberly-Clark Worldwide, Inc. Reduction of the hook effect in membrane-based assay devices
US7265881B2 (en) * 2002-12-20 2007-09-04 Hewlett-Packard Development Company, L.P. Method and apparatus for measuring assembly and alignment errors in sensor assemblies
US8574895B2 (en) * 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US7560272B2 (en) * 2003-01-04 2009-07-14 Inverness Medical Switzerland Gmbh Specimen collection and assay container
US7122153B2 (en) * 2003-01-08 2006-10-17 Ho Winston Z Self-contained microfluidic biochip and apparatus
US7264139B2 (en) 2003-01-14 2007-09-04 Hypoguard Limited Sensor dispensing device
EP2574400B1 (en) 2003-02-05 2016-09-28 Iquum, Inc. Sample processing
US20040166551A1 (en) * 2003-02-24 2004-08-26 John Moulds Detection of agglutination of assays
JP3910148B2 (en) * 2003-03-14 2007-04-25 アークレイ株式会社 Analysis tool with exhaust port
GB0306098D0 (en) 2003-03-18 2003-04-23 Platform Diagnostics Group Ltd Sample testing device
US7851209B2 (en) * 2003-04-03 2010-12-14 Kimberly-Clark Worldwide, Inc. Reduction of the hook effect in assay devices
US20040197819A1 (en) * 2003-04-03 2004-10-07 Kimberly-Clark Worldwide, Inc. Assay devices that utilize hollow particles
US20040219691A1 (en) * 2003-04-29 2004-11-04 Shartle Robert J. Test strip with clear base support layer for visual perception of a liquid sample during application
KR100509254B1 (en) * 2003-05-22 2005-08-23 한국전자통신연구원 Micro-fluidic device to control flow time of micro-fluid
EP1628567B1 (en) 2003-05-30 2010-08-04 Pelikan Technologies Inc. Method and apparatus for fluid injection
DK1633235T3 (en) * 2003-06-06 2014-08-18 Sanofi Aventis Deutschland Apparatus for sampling body fluid and detecting analyte
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
US7604592B2 (en) 2003-06-13 2009-10-20 Pelikan Technologies, Inc. Method and apparatus for a point of care device
US7718439B2 (en) 2003-06-20 2010-05-18 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US8058077B2 (en) 2003-06-20 2011-11-15 Roche Diagnostics Operations, Inc. Method for coding information on a biosensor test strip
US7645421B2 (en) 2003-06-20 2010-01-12 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US8148164B2 (en) 2003-06-20 2012-04-03 Roche Diagnostics Operations, Inc. System and method for determining the concentration of an analyte in a sample fluid
US8071030B2 (en) 2003-06-20 2011-12-06 Roche Diagnostics Operations, Inc. Test strip with flared sample receiving chamber
US7488601B2 (en) 2003-06-20 2009-02-10 Roche Diagnostic Operations, Inc. System and method for determining an abused sensor during analyte measurement
US7645373B2 (en) 2003-06-20 2010-01-12 Roche Diagnostic Operations, Inc. System and method for coding information on a biosensor test strip
US7452457B2 (en) 2003-06-20 2008-11-18 Roche Diagnostics Operations, Inc. System and method for analyte measurement using dose sufficiency electrodes
US8206565B2 (en) 2003-06-20 2012-06-26 Roche Diagnostics Operation, Inc. System and method for coding information on a biosensor test strip
PT1639352T (en) 2003-06-20 2018-07-09 Hoffmann La Roche Method and reagent for producing narrow, homogenous reagent strips
US20040265171A1 (en) * 2003-06-27 2004-12-30 Pugia Michael J. Method for uniform application of fluid into a reactive reagent area
US7517495B2 (en) * 2003-08-25 2009-04-14 Inverness Medical Switzerland Gmbh Biological specimen collection and analysis system
US8282576B2 (en) * 2003-09-29 2012-10-09 Sanofi-Aventis Deutschland Gmbh Method and apparatus for an improved sample capture device
EP1680014A4 (en) 2003-10-14 2009-01-21 Pelikan Technologies Inc Method and apparatus for a variable user interface
US7147362B2 (en) * 2003-10-15 2006-12-12 Agilent Technologies, Inc. Method of mixing by intermittent centrifugal force
US20050084866A1 (en) * 2003-10-15 2005-04-21 Caren Michael P. Methods and apparatus for sample mixing
US7943395B2 (en) * 2003-11-21 2011-05-17 Kimberly-Clark Worldwide, Inc. Extension of the dynamic detection range of assay devices
US7713748B2 (en) * 2003-11-21 2010-05-11 Kimberly-Clark Worldwide, Inc. Method of reducing the sensitivity of assay devices
US20050112703A1 (en) * 2003-11-21 2005-05-26 Kimberly-Clark Worldwide, Inc. Membrane-based lateral flow assay devices that utilize phosphorescent detection
US7476360B2 (en) 2003-12-09 2009-01-13 Genefluidics, Inc. Cartridge for use with electrochemical sensor
US20050136550A1 (en) * 2003-12-19 2005-06-23 Kimberly-Clark Worldwide, Inc. Flow control of electrochemical-based assay devices
US7943089B2 (en) * 2003-12-19 2011-05-17 Kimberly-Clark Worldwide, Inc. Laminated assay devices
DE10360220A1 (en) * 2003-12-20 2005-07-21 Steag Microparts Gmbh Fine structure arrangement in fluid ejection system, has predetermined region in transitional zone between inlet and discharge ports, at which capillary force is maximum
EP1706026B1 (en) 2003-12-31 2017-03-01 Sanofi-Aventis Deutschland GmbH Method and apparatus for improving fluidic flow and sample capture
US7822454B1 (en) * 2005-01-03 2010-10-26 Pelikan Technologies, Inc. Fluid sampling device with improved analyte detecting member configuration
EP1713926B1 (en) 2004-02-06 2012-08-01 Bayer HealthCare, LLC Oxidizable species as an internal reference for biosensors and method of use
DE102004007274A1 (en) * 2004-02-14 2005-09-15 Roche Diagnostics Gmbh Test element for a human or animal fluid sample, e.g. to test for glucose, has a sampling surface and an actuator field to pull the sample to a test field
EP1733232A1 (en) * 2004-03-23 2006-12-20 Quidel Corporation Hybrid phase lateral flow assay
US7248360B2 (en) 2004-04-02 2007-07-24 Ppd Biomarker Discovery Sciences, Llc Polychronic laser scanning system and method of use
US8828203B2 (en) * 2004-05-20 2014-09-09 Sanofi-Aventis Deutschland Gmbh Printable hydrogels for biosensors
EP1765194A4 (en) 2004-06-03 2010-09-29 Pelikan Technologies Inc Method and apparatus for a fluid sampling device
US9775553B2 (en) * 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
DE102004027422A1 (en) * 2004-06-04 2005-12-29 Boehringer Ingelheim Microparts Gmbh Device for receiving blood and separating blood components
US7569126B2 (en) 2004-06-18 2009-08-04 Roche Diagnostics Operations, Inc. System and method for quality assurance of a biosensor test strip
US20060001551A1 (en) * 2004-06-30 2006-01-05 Ulrich Kraft Analyte monitoring system with wireless alarm
US8343074B2 (en) * 2004-06-30 2013-01-01 Lifescan Scotland Limited Fluid handling devices
US20060000709A1 (en) * 2004-06-30 2006-01-05 Sebastian Bohm Methods for modulation of flow in a flow pathway
US7521226B2 (en) * 2004-06-30 2009-04-21 Kimberly-Clark Worldwide, Inc. One-step enzymatic and amine detection technique
US20060002817A1 (en) * 2004-06-30 2006-01-05 Sebastian Bohm Flow modulation devices
US20060021665A1 (en) * 2004-07-29 2006-02-02 Vadym Buyalsky Method of attract-to-merge control of liquid jet-stream flows (AMS method)
GB0423885D0 (en) 2004-10-28 2004-12-01 Platform Diagnostics Ltd Blood analysis
US9260693B2 (en) 2004-12-03 2016-02-16 Cytonome/St, Llc Actuation of parallel microfluidic arrays
US20080214917A1 (en) * 2004-12-30 2008-09-04 Dirk Boecker Method and apparatus for analyte measurement test time
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
US20060184065A1 (en) * 2005-02-10 2006-08-17 Ajay Deshmukh Method and apparatus for storing an analyte sampling and measurement device
US7514256B2 (en) * 2005-02-11 2009-04-07 Emilio Barbera-Guillem Bioreactor for selectively controlling the molecular diffusion between fluids
US7439079B2 (en) * 2005-04-29 2008-10-21 Kimberly-Clark Worldwide, Inc. Assay devices having detection capabilities within the hook effect region
US7858384B2 (en) * 2005-04-29 2010-12-28 Kimberly-Clark Worldwide, Inc. Flow control technique for assay devices
US7803319B2 (en) 2005-04-29 2010-09-28 Kimberly-Clark Worldwide, Inc. Metering technique for lateral flow assay devices
US8192599B2 (en) * 2005-05-25 2012-06-05 Universal Biosensors Pty Ltd Method and apparatus for electrochemical analysis
US8323464B2 (en) * 2005-05-25 2012-12-04 Universal Biosensors Pty Ltd Method and apparatus for electrochemical analysis
KR101321296B1 (en) 2005-07-20 2013-10-28 바이엘 헬스케어 엘엘씨 Gated amperometry temperature determination
JP5671205B2 (en) 2005-09-30 2015-02-18 バイエル・ヘルスケア・エルエルシー Gated voltammetry
US20070276290A1 (en) * 2005-10-04 2007-11-29 Dirk Boecker Tissue Penetrating Apparatus
US20070191736A1 (en) * 2005-10-04 2007-08-16 Don Alden Method for loading penetrating members in a collection device
US20080311585A1 (en) * 2005-11-02 2008-12-18 Affymetrix, Inc. System and method for multiplex liquid handling
US8007267B2 (en) * 2005-11-02 2011-08-30 Affymetrix, Inc. System and method for making lab card by embossing
US8075852B2 (en) * 2005-11-02 2011-12-13 Affymetrix, Inc. System and method for bubble removal
US20070099288A1 (en) * 2005-11-02 2007-05-03 Affymetrix, Inc. Microfluidic Methods, Devices, and Systems for Fluid Handling
US20080038714A1 (en) * 2005-11-02 2008-02-14 Affymetrix, Inc. Instrument to Pneumatically Control Lab Cards and Method Thereof
US7279136B2 (en) 2005-12-13 2007-10-09 Takeuchi James M Metering technique for lateral flow assay devices
US7618810B2 (en) 2005-12-14 2009-11-17 Kimberly-Clark Worldwide, Inc. Metering strip and method for lateral flow assay devices
DE102005062723B4 (en) * 2005-12-22 2007-11-22 INSTITUT FüR MIKROTECHNIK MAINZ GMBH Sample processing chip, reaction chamber and use of the sample processing chip
CN1987479A (en) * 2005-12-23 2007-06-27 博奥生物有限公司 Micro fluid chamber for preventing liquid from flowing along tube wall wedge angle in hydrophilic micro fine tube
US7871568B2 (en) * 2006-01-23 2011-01-18 Quidel Corporation Rapid test apparatus
US7794656B2 (en) * 2006-01-23 2010-09-14 Quidel Corporation Device for handling and analysis of a biological sample
CN101384900B (en) 2006-02-21 2013-06-05 环球生物医疗感测仪私人有限公司 Fluid transfer mechanism
JP4775039B2 (en) * 2006-03-03 2011-09-21 パナソニック株式会社 Microfluidic chip
WO2007133456A2 (en) * 2006-05-08 2007-11-22 Bayer Healthcare Llc Test sensor with under-fill protection
US20080021364A1 (en) * 2006-07-17 2008-01-24 Industrial Technology Research Institute Fluidic device
US8403557B2 (en) * 2006-09-28 2013-03-26 University Of Washington Micromixer using integrated three-dimensional porous structure
JP2010505393A (en) * 2006-09-28 2010-02-25 ユニヴァーシティ オブ ワシントン 3D microscale artificial tissue model system
WO2008061130A2 (en) * 2006-11-15 2008-05-22 Ucp Biosciences, Inc. An improved collecting and testing device and method of use
CN101652660B (en) * 2007-02-26 2017-09-01 干细胞技术公司 Reduce the method for the meniscus curvature of fluid nutrient medium
WO2009076302A1 (en) 2007-12-10 2009-06-18 Bayer Healthcare Llc Control markers for auto-detection of control solution and methods of use
WO2009126900A1 (en) 2008-04-11 2009-10-15 Pelikan Technologies, Inc. Method and apparatus for analyte detecting device
CA2678570C (en) * 2008-09-12 2016-08-16 Stemcell Technologies Inc. Cell culture vessels for meniscus reduction with aqueous solutions
WO2010070521A1 (en) 2008-12-18 2010-06-24 Koninklijke Philips Electronics N.V. Sensing device for sensing a fluid
US20100187132A1 (en) * 2008-12-29 2010-07-29 Don Alden Determination of the real electrochemical surface areas of screen printed electrodes
US9375169B2 (en) * 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
CN113092562B (en) 2009-04-17 2024-03-29 环球生物医疗感测仪私人有限公司 Electrochemical on-board control detection
CN104950102A (en) * 2009-07-24 2015-09-30 阿科尼生物系统公司 Flow cell device
EP2512677B1 (en) * 2009-12-18 2018-08-15 Abbott Point Of Care, Inc. Integrated hinged cartridge housings for sample analysis
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
EP2486978A1 (en) 2010-10-28 2012-08-15 Roche Diagnostics GmbH Microfluid test carrier for separating a fluid volume in partial volumes
EP2455162A1 (en) 2010-10-29 2012-05-23 Roche Diagnostics GmbH Microfluidic element for analysing a fluid sample
US9044757B2 (en) * 2011-03-15 2015-06-02 Carclo Technical Plastics Limited Capillary fluid flow control
JP2012202925A (en) * 2011-03-28 2012-10-22 Rohm Co Ltd Analytical chip, analytical system and analytical method
WO2013008442A1 (en) * 2011-07-14 2013-01-17 株式会社エンプラス Fluid handling device, fluid handling method, and fluid handling system
DE102011079698B4 (en) * 2011-07-25 2022-08-04 Robert Bosch Gmbh Microfluidic device having a chamber for storing a liquid
EP2555039B1 (en) * 2011-08-05 2017-08-23 Samsung Electronics Co., Ltd. Electrofluidic chromatophore (EFC) display apparatus
JP2014525569A (en) * 2011-08-30 2014-09-29 ザ・ロイヤル・インスティテューション・フォア・ザ・アドバンスメント・オブ・ラーニング/マクギル・ユニヴァーシティ Method and system for a pre-programmed self-output microfluidic circuit
WO2013105678A1 (en) * 2012-01-11 2013-07-18 경원대학교 산학협력단 Blood glucose measurement unit, blood glucose measurement system comprising same, and blood glucose measurement method
WO2013154946A1 (en) * 2012-04-11 2013-10-17 Alere San Diego, Inc. Microfluidic device, system and method
US20130341207A1 (en) * 2012-06-21 2013-12-26 Lifescan Scotland Limited Analytical test strip with capillary sample-receiving chambers separated by stop junctions
GB2505706A (en) * 2012-09-10 2014-03-12 Univ Leiden Apparatus comprising meniscus alignment barriers
WO2014062719A2 (en) 2012-10-15 2014-04-24 Nanocellect Biomedical, Inc. Systems, apparatus, and methods for sorting particles
US10537891B2 (en) 2013-01-10 2020-01-21 Stemcell Technologies Inc. Meniscus reducing member
CN105073587B (en) 2013-01-10 2018-01-09 干细胞技术公司 Meniscus reduces component
CA2906730C (en) 2013-03-14 2023-03-21 Juan G. Santiago Capillary barriers for staged loading of microfluidic devices
RU2629098C1 (en) 2014-04-30 2017-08-24 Кимберли-Кларк Ворлдвайд, Инк. Absorbent product containing fluid medium distributing structure
US10073091B2 (en) * 2014-08-08 2018-09-11 Ortho-Clinical Diagnostics, Inc. Lateral flow assay device
US11033896B2 (en) * 2014-08-08 2021-06-15 Ortho-Clinical Diagnostics, Inc. Lateral-flow assay device with filtration flow control
CN109415722A (en) 2016-01-29 2019-03-01 普瑞珍生物系统公司 Isotachophoresis for nucleic acid purification
US11604189B2 (en) 2017-04-28 2023-03-14 Leadway (Hk) Limited Detection device capable of visual test results
CA3071816A1 (en) 2017-08-02 2019-02-07 Purigen Biosystems, Inc. Systems, devices, and methods for isotachophoresis
JP6871128B2 (en) * 2017-10-20 2021-05-12 アークレイ株式会社 Biosensor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE399768B (en) * 1975-09-29 1978-02-27 Lilja Jan E CYVETT FOR SAMPLING, MIXING OF, THE SAMPLE WITH A REAGENTS AND DIRECT PERFORMANCE OF, SPECIAL OPTICAL, ANALYSIS OF THE SAMPLE MIXED WITH THE REAGENTS
US4227810A (en) * 1978-01-26 1980-10-14 Technicon Instruments Corporation Cuvette and method of use
US4233029A (en) * 1978-10-25 1980-11-11 Eastman Kodak Company Liquid transport device and method
DE3067436D1 (en) * 1979-07-23 1984-05-17 Eastman Kodak Co Liquid transport device for controlled liquid flow, and liquid testing device and device for determining activity of an ionic analyte including a liquid transport device

Also Published As

Publication number Publication date
EP0057110B1 (en) 1985-04-17
JPH028775B2 (en) 1990-02-27
EP0057110B2 (en) 1990-01-03
DE3263066D1 (en) 1985-05-23
US4426451A (en) 1984-01-17
EP0057110A2 (en) 1982-08-04
JPS57156028A (en) 1982-09-27
EP0057110A3 (en) 1982-08-18

Similar Documents

Publication Publication Date Title
CA1189431A (en) Multi-zoned reaction vessel having pressure- actuatable control means between zones
CA1300006C (en) Self-contained immunoassay element
US7459127B2 (en) Method and apparatus for precise transfer and manipulation of fluids by centrifugal and/or capillary forces
US10598572B2 (en) Sequential lateral capillary flow device for analyte determination
US10335783B2 (en) Multistep reaction lateral flow capillary device
US6120733A (en) Self-contained assay device
EP1388006B9 (en) In line test device and methods of use
EP0733211B1 (en) Interrupted-flow assay device
CA2021587C (en) Automated method and device for performing solid-phase diagnostic assay
US20110124130A1 (en) Device and method for analysis of samples with depletion of analyte content
US5622870A (en) Device and method for completing a fluidic circuit

Legal Events

Date Code Title Description
MKEX Expiry